Healthcare Middle East & Africa magazine - Issue 14

Year 3 | Issue No. 14 | Jan-Mar 2025

FOUNDER & PUBLISHER

Francis Juma

SENIOR EDITOR

Alphonse Okoth

EDITOR

Vincent Moranga

BUSINESS DEVELOPMENT

DIRECTOR

Virginia Nyoro

BUSINESS DEVELOPMENT ASSOCIATE

Jackie Muinde

HEAD OF DESIGN

Clare Ngode

DESIGN

OUR MAGAZINES

MIDDLE EAST & AFRICA www.hotelhospitalitymea.com

Monica Wachio

ACCOUNTS

Jonah Sambai

PUBLISHED BY: FW Africa

P.O. Box 1874-00621, Nairobi Kenya

Tel: +254 725 34 39 32

Email: info@fwafrica.net Company Website: www.fwafrica.net

We publish some of the most influential magazines and websites in Africa & the Middle East regions. Please visit the websites below for more information about our publications

www.millingmea.com

www.dairybusinessafrica.com

www.labmanagementmea.com

HealthCare Africa (ISSN 2307-3535) is published 4 times a year by FW Africa. Reproduction of the whole or any part of the contents without written permission from the editor is prohibited. All information is published in good faith. While care is taken to prevent inaccuracies, the publishers accept no liability for any errors or omissions or for the consequences of any action taken on the basis of information published.

www.healthcaremea.com

Marking World Kidney Day – A call to protect a vital organ

Every year, World Kidney Day casts a much-needed spotlight on one of the body’s most hardworking yet frequently overlooked organs. Our kidneys play a critical role in maintaining overall health—they filter waste, balance fluids, regulate blood pressure, and support red blood cell production. Yet, kidney disease continues to rise globally, often progressing silently until it reaches advanced stages.

This year’s theme, “Are Your Kidneys OK? Detect Early, Protect Kidney Health,” emphasizes the urgent need for early detection and prevention. Most people with early-stage kidney disease show no symptoms. Without timely intervention, it can escalate into chronic kidney failure, requiring dialysis or transplantation—both of which remain out of reach for many in low- and middle-income countries.

Prevention is still our strongest line of defence. Public health campaigns must prioritise regular checkups, particularly for high-risk individuals—those with diabetes, hypertension, obesity, or a family history of kidney disease. Communities must also be empowered through education: encouraging adequate hydration, reducing salt intake, avoiding the misuse of over-the-counter painkillers, and embracing active, healthy lifestyles.

In recent years, healthcare providers and NGOs have stepped up efforts through mobile clinics, community outreach, and free screening initiatives around World Kidney Day. These actions are helping to reach underserved and remote populations. However, governments must do more— by investing in affordable dialysis infrastructure, subsidizing

medications, and incorporating kidney care into national health insurance schemes.

Ultimately, kidney health is a shared responsibility. By raising awareness, supporting early intervention, and improving access to care, we can stem the rising tide of kidneyrelated illness. On this World Kidney Day, let us recommit to protecting kidney health—not just for ourselves, but for everyone, regardless of their background or economic status.

As we mark this important health calendar day, I warmly invite you to explore our 14th issue of Healthcare Middle East & Africa magazine. In this edition, we feature Lions SightFirst Eye Hospital (LSEH), a facility that has consistently delivered quality eye care while addressing related health challenges.

We also bring you insightful pieces on weight loss management, where Hillary Yegon explores the latest innovations in treatment—including new-generation weight loss drugs. Vincent Moranga covers the re-emergence of the Marburg virus in East Africa and delves into regional and global strategies to manage its spread. He also highlights the growing role of artificial intelligence (AI) in modern eye care.

Get these stories and much more in the region’s No.1 healthcare and pharmaceutical industry magazine.

Enjoy the read!

Alphonse Okoth Senior Editor FW Africa

Africa CDC renew deal with Illumina to strengthen pathogen genomics across Africa

AFRICA — The Africa Centres for Disease Control and Prevention (Africa CDC) and Illumina, a global leader in sequencing technology, have announced the renewal of their collaborative partnership to advance the Africa Pathogen Genomics Initiative (Africa PGI).

This renewed commitment aims to bolster public health surveillance and laboratory networks across Africa by expanding access to and expertise in next-generation sequencing (NGS) tools.

H.E. Dr. Jean Kaseya, DirectorGeneral of Africa CDC, emphasized the transformative potential of genomics in disease surveillance, stating that the collaboration will strive to equip all 55 National Public Health Institutes (NPHIs) with operational NGS capacity by the end of 2025.

This enhanced capability will significantly improve Africa’s ability to detect and respond effectively to emerging health threats.

As part of the renewed commitment, additional sequencing instruments and reagents will be distributed to approximately 25 African countries, ensuring broader access to these vital technologies.

global health through the power of genomics.

She highlighted that expanding access to cutting-edge sequencing technologies will empower countries to detect and respond to health threats rapidly, ultimately saving countless lives.

Since the partnership’s inception in March 2021, Illumina has been a crucial contributor, providing NGS platforms, reagents, and comprehensive training support.

The partnership expands Africa PGI, launched in October 2020 as a flagship initiative of Africa CDC, that focuses on integrating pathogen genomics and bioinformatics into public health systems. PARTNERSHIPS

Building upon four years of successful joint efforts in addressing COVID-19, other infectious diseases, and endemic health threats such as tuberculosis, malaria, and cholera, this partnership seeks to further integrate NGS into routine public health systems.

Belinda Ngongo, Director of Global Health at Illumina, reiterated the company’s dedication to improving

Genentech’s Evrysdi Tablet gains FDA approval for spinal muscular atrophy

USA — Genentech, a member of the Roche Group, has announced that the U.S. Food and Drug Administration (FDA) has approved a new tablet formulation of Evrysdi (risdiplam) for the treatment of spinal muscular atrophy (SMA)

This approval marks a crucial milestone in providing an additional treatment option for individuals affected by this severe and progressive neuromuscular disease.

Evrysdi is the only non-invasive disease-modifying treatment for SMA, offering a groundbreaking approach to managing this condition.

The newly approved 5 mg tablet can be taken whole or dissolved in water, providing a more convenient alternative for patients compared to existing treatments.

This administration flexibility is

expected to enhance the quality of life for those living with SMA, allowing for easier management of the disease during daily activities such as work, travel, and education.

The FDA’s approval of the Evrysdi tablet is based on a bioequivalence study, which confirmed that the new tablet provides the same level of drug absorption as the original oral solution.

With this label extension, Evrysdi’s prescribing information now includes guidance on tablet administration and storage.

The new tablet, expected to be available in the coming weeks, is suitable for individuals aged two years and older who weigh at least 44 pounds (20 kg).

Since its initial approval, Evrysdi has gained widespread recognition, receiving PRIME designation from the European Medicines Agency (EMA)

in 2018 and Orphan Drug Designation from the FDA in 2017.

In 2021, the British Pharmacological Society awarded it Drug Discovery of the Year and the Society for Medicines Research Award for Drug Discovery.

Currently, Evrysdi is approved in over 100 countries, and the treatment benefits more than 16,000 patients worldwide.

INVESTMENT

Italian Firm invests US$100M in Egyptian healthcare, education

EGYPT - Italy’s San Donato Hospital Group is making a bold new investment that will make a major contribution to Egypt’s healthcare and education sectors.

The Italian firm announced plans to invest US$100 million in the first phase of a hospital project, with further expansion planned across several governorates.

This significant announcement was made during a meeting between Prime Minister Mostafa Madbouly and Kamel Ghribi, Chairman of GSD and GKSD Holding Group for Investment.

In addition to the hospital, the investment plan includes establishing an international university specializing in medical sciences.

The Italian group has already begun discussions with Egyptian authorities to secure suitable land or to repurpose existing buildings for the new university.

This dual approach aims not only to provide world-class healthcare facilities but also to foster advanced medical education and research in Egypt.

Prime Minister Madbouly welcomed the proposal with enthusiasm, stressing that both healthcare and education are pivotal for Egypt’s long-term development.

He reaffirmed that the government is fully committed to attracting foreign investments in these strategic areas.

Minister of Health Khaled Abdel Ghaffar added that the San Donato Hospital Group had been carefully studying the Egyptian market for several years before moving ahead with the project.

The planned 140-bed hospital in New Cairo is designed to feature state-of-the-art medical technologies, ensuring that its services are on par with international standards.

This modern facility is expected to significantly enhance the quality and accessibility of healthcare in the region.

Kamel Ghribi also commended Egypt’s rapid development, particularly the progress seen in the New Administrative Capital, and highlighted the hospital group’s expertise in over 50 medical specialties.

With robust government backing and international investment, these projects promise to transform Egypt’s healthcare landscape and stimulate further economic growth.

Emirates partners with Parsys to introduce advanced inflight telemedicine

UAE - Emirates has partnered with Parsys Telemedicine to launch an advanced inflight telemedicine system, aiming to enhance onboard medical care.

The airline has invested over US$2.4 million in codeveloping a custom telemedicine kit with Parsys, which will be installed on 300 aircraft over the next few years.

The new ‘telemedicine station’ features high-definition video conferencing, real-time passenger assessment, secure data transmission, and 12-lead ECG capabilities.

This system equips Emirates’ cabin crew to manage medical emergencies more effectively during flights.

The system includes the Parsys Telemedicine Kit and the Parsys Cloud, enabling cabin crew to collect and transmit vital signs—such as oxygen, blood, and glucose—directly to Emirates’ Ground Medical Support team in Dubai. This team operates 24/7 to offer immediate medical guidance.

The Medcapture tablet streamlines the process by automatically receiving Bluetooth-transmitted data, reducing the need for manual note-taking.

Its intuitive design allows crew to operate the system efficiently, even under stress, while maintaining real-time communication with doctors on the ground.

Already deployed on multiple aircraft, the new system has played a critical role in managing inflight emergencies.

The Parsys kit is introduced through a mix of e-learning and hands-on practice. Crew members also receive annual refresher training and flight simulation assessments to keep their skills sharp.

Emirates emphasizes technical proficiency and psychological readiness, teaching crew how to communicate empathetically and manage emotionally charged situations.

Support is also available to crew through mental health programs after handling critical incidents.

This holistic approach underscores Emirates’ commitment to passenger safety and crew wellbeing, marking a new era of inflight medical care.

DISEASE UPDATES

Uganda launches Ebola vaccine trial for Sudan species

UGANDA — The Ugandan Ministry of Health, in collaboration with the World Health Organization (WHO) and other global partners, has initiated the first-ever clinical efficacy trial for a vaccine against the Sudan species of the Ebola virus.

This pioneering effort follows the recent confirmation of a case of Ebola Sudan virus disease (SVD) in a nurse from Mulago National Referral Hospital in Kampala.

The trial is notable for its unprecedented speed, being set up in just four days after the outbreak was confirmed. It also maintains rigorous compliance with international and national regulatory and ethical standards.

The vaccine, donated by the International AIDS Vaccine Initiative (IAVI), has previously undergone safety and immune response trials.

This marks the first time it is being tested in an outbreak setting to evaluate its clinical effectiveness.

The trial is led by principal investigators from Makerere University and the Uganda Virus Research Institute (UVRI), with strong support from WHO and other partners.

Financial backing for the trial comes from WHO, the Coalition for Epidemic Preparedness Innovations (CEPI), Canada’s International Development Research Centre (IDRC), and the European Commission’s Health Emergency Preparedness and Response Authority (HERA), with additional support from the Africa Centres for Disease Control and Prevention (Africa CDC).

Uganda has been preparing for such a trial since 2022, when a previous Ebola Sudan outbreak led to developing a randomized protocol for candidate vaccines.

Currently, there is no licensed vaccine for the Ebola Sudan virus disease, although vaccines are available for the Zaire strain of the Ebola virus.

Additionally, approved treatments are currently only available for the Zaire strain, not the Sudan species.

This trial represents a critical step towards addressing this gap and enhancing global pandemic preparedness.

If successful, it could play a pivotal role in controlling future outbreaks and supporting the regulatory approval of the candidate vaccine.

Sanofi to sell Opella Consumer Health stake for US$17B

FRANCE — French pharmaceutical giant Sanofi has announced plans to formalize the sale of its consumer health division, Opella, in a deal valued at approximately US$17 billion.

This transaction, facilitated through a definitive share purchase agreement with Clayton Dubilier & Rice (CD&R), marks a pivotal moment in Sanofi’s strategic transformation into a pure-play biopharmaceutical company.

Under the agreement, Sanofi will transfer a 50% controlling stake in Opella to CD&R while maintaining a substantial equity position.

This strategic partnership is complemented by the French public investment bank Bpifrance, which is set to acquire a 2% minority stake.

This move not only reinforces Opella’s national significance but also aligns with the French government’s objectives of safeguarding domestic jobs and production capabilities.

This development represents Sanofi’s first public confirmation since it entered exclusive negotiations with CD&R in October 2024.

The transaction, subject to customary regulatory clearances, is projected to conclude by the second quarter of 2025.

Opella, a major player in the global consumer health market, boasts a workforce exceeding 11,000 employees worldwide. It operates in over 100 countries, with 13 manufacturing sites and four science and innovation development centers.

Opella’s product portfolio is anchored by iconic brands, most notably Doliprane, a paracetamol-based analgesic that has achieved near-generic status in France, where its name is often used interchangeably with “paracetamol.”

Beyond Doliprane, Opella’s offerings include Allegra, a widely used allergy medication, and Buscopan, a trusted remedy for irritable bowel syndrome (IBS) symptoms. Additionally, Opella develops and markets other notable products such as Dulcolax.

Sanofi’s divestment of Opella is not merely a financial maneuver but a key component of the company’s overarching strategy to evolve into a pure-play biopharmaceutical leader to focus on its core pharmaceutical operations, including innovative medicines and vaccines.

REGULATORY

Dr. Kalebi Labs receives ISO 15189 Certification

KENYA - Dr. Kalebi Labs (DKL) has officially received ISO 15189 certification from the Kenya National Accreditation Service (KENAS, following a successful assessment of DKL’s Central Referral Lab conducted on November 26-27, 2024.

The lab, which has been operational for just a few months, marks a new chapter in Dr. Ahmed Kalebi’s journey in medical diagnostics.

DKL was established after Dr. Kalebi left Pathologists Lancet Kenya (Lancet), a diagnostic laboratory he founded over 15 years ago.

Since May 2021, Dr. Kalebi has been working as an independent consultant pathologist under his Specialist Practice License, registered with the Kenya Medical Practitioners and Dentists Council (KMPDC) through his private limited company, Ahmed Kalebi Consultancy.

NEWS THIS FULLY AUTOMATED LABORATORY WILL ENHANCE ACCESS TO HIGH-QUALITY MEDICAL TESTING AND REDUCING TURNAROUND TIMES

The journey to ISO certification was remarkably swift, with DKL beginning construction and setup in May 2024.

Just three months later, in September 2024, the lab was registered by the Kenya Medical Laboratory Technicians and Technologists Board (KMLTTB) as a Class G National and International Referral Lab.

This fully automated laboratory will transform the healthcare landscape in the region by enhancing access to highquality medical testing and reducing turnaround times for patients and healthcare providers.

DKL distinguishes itself as a unique facility on the African continent by employing cutting-edge Total Lab Automation (TLA) technology for various testing platforms, including chemistry, immunoassay, hematology, molecular diagnostics, tissue and digital pathology, as well as coagulation testing.

The laboratory is equipped with advanced diagnostic machines capable of performing a wide array of tests, ranging from routine blood work to complex genetic testing.

By leveraging artificial intelligence and robotics, Dr. Kalebi Labs aims to minimize human error, provide patients with reliable results, and enable faster clinical decisions for healthcare professionals.

Novartis to acquire Anthos Therapeutics in potential US$3B deal

USA — Swiss pharmaceutical powerhouse Novartis has announced a definitive agreement to acquire Anthos Therapeutics, a Boston-based clinicalstage biopharmaceutical company, in a deal that could be worth US$3.075 billion.

The initial upfront payment of US$925 million, subject to standard adjustments, will be made upon the transaction’s completion.

Further payments, potentially totalling up to US$2.15 billion, are contingent upon achieving pre-defined regulatory and sales milestones, reflecting the promising potential of Anthos’s lead asset.

The acquisition, pending customary closing conditions, is expected to finalise in the first half of 2025.

Anthos Therapeutics, established in 2019 through a collaborative effort between Blackstone Life Sciences and

Novartis, has focused on developing abelacimab, a groundbreaking treatment designed to prevent stroke and systemic embolism in patients with atrial fibrillation.

This strategic acquisition aligns seamlessly with Novartis’s overarching strategy to expand its cardiovascular portfolio, leveraging its established expertise in this critical therapeutic area. Abelacimab represents a significant advancement in anticoagulation therapy.

This novel, fully human monoclonal antibody functions by selectively inhibiting Factor XI, a key component of the blood clotting cascade.

This innovative mechanism aims to reduce the risk of thrombosis, or blood clot formation, without the increased bleeding complications commonly associated with traditional bloodthinning medications.

The clinical potential of abelacimab

has been demonstrated in Phase 2 trials, where it significantly reduced bleeding events compared to standard anticoagulants in patients with atrial fibrillation.

Building on these promising results, three pivotal Phase 3 clinical trials are currently underway. These trials are designed to evaluate abelacimab’s efficacy and safety in patients at risk of arterial and venous clots.

Specifically, the LILAC-TIMI 76 trial focuses on atrial fibrillation, while the ASTER4 and MAGNOLIA trials examine the drug’s potential in cancer-associated thrombosis.

Abelacimab has already received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for both cancer-associated thrombosis and stroke prevention in atrial fibrillation.

Mpox emergency status extended in Africa

AFRICA — The Emergency Consultative Group (ECG) of the Africa Centres for Disease Control and Prevention (Africa CDC) has unanimously recommended that Mpox remain classified as a Public Health Emergency of Continental Security (PHECS).

This decision follows a thorough evaluation of the outbreak’s current status, highlighting several concerning trends over the past few months.

The weekly average of reported Mpox cases has seen a dramatic increase, rising from 909 cases in August 2024 to approximately 3,264 cases in February 2025.

Professor Salim Abdool Karim, chair of the ECG, emphasized the importance of continued attention to these developments.

A significant factor contributing to the heightened concern is the emergence

of a new, highly transmissible variant known as Clade Ia (APOBEC3). This variant poses increased public health risks, necessitating enhanced measures to combat its spread.

The ECG’s review identified gaps in surveillance and testing, as well as suboptimal vaccination strategies, as major concerns.

Despite efforts to manage the outbreak, case underreporting remains a significant issue, obscuring the true extent of the crisis.

Deteriorating security conditions in areas like the Eastern Democratic Republic of the Congo (DRC) have further complicated effective outbreak management.

The recent suspension of U.S. foreign aid has disrupted critical activities such as sample collection and transportation, exacerbating the challenges faced by

Guinea eliminates sleeping sickness

GUINEA — Guinea has been recognized for eliminating the gambiense form of human African trypanosomiasis (HAT), commonly known as sleeping sickness, as a public health problem.

According to the World Health Organization (WHO), this landmark achievement, announced to coincide with World Neglected Tropical Diseases Day on 30 January, represents Guinea’s first successful elimination of a neglected tropical disease (NTD).

Sleep sickness is a life-threatening parasitic disease transmitted through tsetse fly bites.

Early symptoms include fever, headaches, and joint pain, which can progress to severe neurological complications such as confusion, disrupted sleep patterns, and behavioural changes.

Guinea’s success in combating this disease stems from a comprehensive strategy initiated in 2002 by the

Ministry of Health and Public Hygiene.

The National Programme for the Control of HAT prioritised mass medical screenings to detect and treat cases early, supported by the WHO, Institut de Recherche pour le Développement (IRD), and other partners like the Drugs for Neglected Diseases initiative (DNDi).

A major breakthrough occurred in 2012 with the introduction of vector control measures to reduce humantsetse fly contact.

This strategy, piloted in Boffa-East and expanded nationwide by 2016, involved deploying approximately 15,000 insecticide-treated mini-screens annually to attract and kill tsetse flies.

These efforts drastically reduced HAT cases by combining diagnostics advancements, improved treatment access, and sustained technical and financial support from global partners.

By 2024, Guinea had fallen below WHO’s threshold of one case per 10,000

health officials.

Additionally, Africa is grappling with multiple other infectious disease outbreaks, including Ebola, Marburg, measles, cholera, and other febrile illnesses. These concurrent crises are straining already fragile health systems across the continent.

In response to these challenges, the Continental Incident Management Support Team (IMST), co-led by Africa CDC and the World Health Organization (WHO), will collaborate closely with national health ministries, regional partners, and global stakeholders.

Their joint efforts will focus on expanding vaccination campaigns, improving access to diagnostics, and strengthening the resilience of health systems.

inhabitants in endemic areas, with only 12 cases reported that year.

This achievement places Guinea alongside seven other African countries that have eliminated gambiense HAT: Togo (2020), Benin (2021), Côte d’Ivoire (2021), Uganda (2022), Equatorial Guinea (2022), Ghana (2023), and Chad (2024).

Rwanda also eliminated the rhodesiense form of the disease in 2022.

MERGERS & ACQUISITION

Burjeel Holdings expands cancer care in the GCC with strategic acquisition

UAE — Burjeel Holdings, a leading healthcare provider in the Middle East and North Africa region, has acquired an 80% stake in Dubai’s Advanced Care Oncology Center (ACOC) for AED 92 million (US$25.05m).

This strategic acquisition is part of Burjeel’s ambitious plan to establish a premier radiation oncology network across the Gulf Cooperation Council (GCC) countries.

ACOC, renowned for its specialized expertise in radiation therapy, nuclear medicine, and chemotherapy, is a crucial addition to Burjeel’s expanding oncology platform.

In 2024, ACOC generated revenue of AED 64 million (US$17.42 million), demonstrating its strong operational foundation.

The center’s integration into Burjeel’s network will address the unmet needs in underserved areas across the GCC by establishing standalone ACOC-branded centers with cuttingedge technology.

These centers will feature advanced linear accelerators (LINAC), AI-driven radiation planning, and precision imaging tools, ensuring patients can access the latest treatments.

This strategic positioning complements Burjeel’s existing oncology services, particularly the Burjeel Cancer Institute (BCI), one of the largest cancer care networks in the UAE.

BCI offers a comprehensive range of treatments across Abu Dhabi, Al Ain, Al Dhafra, Sharjah, and Dubai facilities, including surgical oncology, immunotherapy, robotic surgery, and bone marrow transplants.

Integrating ACOC into this system will enhance patient care pathways and streamline referrals to specialized services, ensuring a seamless transition for patients requiring advanced therapies.

Burjeel will leverage Oracle Health’s Electronic Medical Record (EMR) system to enhance the network’s capabilities further.

This technology will drive medical research and innovation, focusing on preventive oncology and precision medicine.

Integrating advanced technology and comprehensive data management will solidify Burjeel’s leadership in cancer care, enabling more effective treatment outcomes and advancing regional oncology research.

CFAO Healthcare to acquire full control of Goodlife Pharmacy Chain

KENYA — CFAO Healthcare, the French CFAO Group healthcare division under the Toyota umbrella, has announced plans to acquire the remaining 69.9% stake in Goodlife, the largest private pharmacy chain in East Africa.

This strategic acquisition will be made from investor Leapfrog Investments, following previous transactions that increased CFAO Healthcare’s ownership in Goodlife to 30.1% in 2022.

CFAO Healthcare is a leading player in the African pharmaceutical market, distributing products and medicines across more than 23 countries. The company ensures a streamlined supply chain and maintains integrity from the warehouse to the pharmacy.

In addition to its role as a wholesaler-distributor and agent for internationally recognized laboratories, CFAO Healthcare also produces licensed drugs in Morocco and Algeria.

The upcoming acquisition will be executed through Goodlife’s Mauritius-based holding company, Africa Chemist & Beauty Care Inc. (ACBC).

This will allow CFAO Healthcare to own Goodlife Pharmacy Limited in Kenya and Africa Chemist and Beauty Care Uganda Limited in Uganda, further strengthening its strategic control over the brand in both countries.

Leapfrog first invested in Goodlife in 2017 and has been the majority shareholder, with CFAO Healthcare as the secondlargest shareholder until now.

Goodlife, founded in 2014, has established itself as East Africa’s leading private pharmacy chain. It operates 141 locations, with 133 in Kenya and 8 in Uganda, serving over 1.7 million customers.

The chain offers reliable pharmaceuticals and highquality over-the-counter medications, focusing on individual customer care.

Additionally, Goodlife provides beauty and personal care products, along with digital and home delivery services, making it a comprehensive healthcare provider in the region.

This acquisition follows another significant expansion initiative by CFAO Healthcare in October 2024, when it acquired Opella Healthcare South Africa, a respected local manufacturer and distributor.

INVESTMENT

MSD invests US$1B in advanced US vaccine facility

USA - Merck Sharp & Dohme (MSD) has launched a US$1 billion state-of-the-art vaccine manufacturing facility in Durham, North Carolina, marking a major milestone in its commitment to expand domestic production capabilities.

Spanning 225,000 square feet, the facility is part of MSD’s broader US investment strategy, which includes US$12 billion in capital projects since 2018 and a projected additional US$8 billion by 2028.

This new site is designed to redefine vaccine manufacturing through the integration of cutting-edge technologies such as generative AI, 3D printing, and advanced data analytics.

It also features a training center with a “digital twin”—a virtual replica of the manufacturing process that enhances employee training and allows for safe testing of process changes.

Sanat Chattopadhyay, President of MSD’s manufacturing division, underscored the facility’s strategic importance, “Expanding our state-of-the-art facility in Durham underscores our commitment to innovation and our mission to support patients worldwide.”

He added that these advancements will enable MSD to deliver high-quality vaccines more efficiently.

Amanda Taylor, plant manager and site VP, emphasized the local impact, saying the investment highlights Durham’s role in driving forward MSD’s innovation.

She praised the team’s dedication and energy in shaping the next chapter of the company’s manufacturing capabilities.

The facility draws on best practices from MSD’s global network and represents a cornerstone in its strategy to address public health challenges with advanced medicines and vaccines.

The investment comes shortly after MSD’s oral HIF-2 inhibitor, Welireg, received conditional approval from the European Commission in February 2025 for treating von Hippel-Lindau disease linked to advanced clear cell renal cell carcinoma.

Together, these developments signal MSD’s strong focus on innovation, patient-centered care, and global health leadership.

South Sudan Opens new infectious disease facility at Nimule Border

SOUTH SUDAN - South Sudan’s Ministry of Health, in partnership with the World Health Organization (WHO), has inaugurated a new Infectious Diseases Unit at the Nimule border, officially handed over to the Magwi County Health Department.

With a 15-bed capacity, the facility significantly strengthens the nation’s ability to detect, manage, and contain infectious diseases, particularly at key border entry points.

The facility’s construction began in 2022 following an Ebola Virus Disease (EVD) outbreak in neighboring Uganda.

It is a strategic part of South Sudan’s broader efforts to improve emergency preparedness and reduce cross-border disease transmission risks.

The unit aligns with International Health Regulations (IHR 2005), which urge countries to bolster surveillance and healthcare capabilities at border points.

Given South Sudan’s close epidemiological ties with Uganda and the ongoing outbreak of Sudan Virus Disease there, the operationalization of this center is timely.

The country has also intensified monitoring of other highrisk diseases such as Cholera, Mpox, and Viral Haemorrhagic Fever, using its national preparedness plans and the multidisease outbreak Incident Management System (IMS) to coordinate its response.

WHO Representative Dr. Humphrey Karamagi stressed the importance of surveillance, noting that advanced screening protocols are being implemented at major border crossings.

Multidisciplinary teams supported by WHO have been deployed to Nimule and Kajokeji to conduct risk assessments and prioritize early detection and management of potential EVD cases.

Dr. Harriet Pasquale Akello, Undersecretary of the Ministry of Health, stated that the primary goal of the new unit is to protect communities by enhancing rapid response capabilities.

This facility also addresses critical gaps highlighted in the 2024 Joint External Evaluation (JEE), which emphasized the urgent need for improvements at border entry points.

HOSPITALS

Johns Hopkins opens advanced oncology center in Saudi Arabia

SAUDI ARABIA — Johns Hopkins Aramco Healthcare (JHAH) has officially opened its state-of-the-art Oncology Center of Excellence in Saudi Arabia, marking a major milestone in advancing cancer care across the Gulf Cooperation Council (GCC).

This groundbreaking facility combines Johns Hopkins Medicine’s globally renowned oncology expertise with Saudi Arabia’s advanced healthcare infrastructure, delivering personalized treatment solutions tailored to the region’s unique needs.

Cancer rates in the GCC are projected to rise by over 140% between 2020 and 2040, underscoring the urgent need for specialized oncology care.

The Oncology Center of Excellence addresses this challenge by offering a comprehensive, patient-centered approach to cancer treatment. It specializes in managing breast,

colorectal, and prostate cancers—three of the most prevalent types in the region—through services that include early detection, precision diagnostics, advanced therapies, and survivorship programs.

The center’s holistic model of care ensures that patients receive cuttingedge medical treatments and ongoing support throughout their cancer journey.

By adhering to evidence-based protocols and utilizing advanced medical technologies, the facility sets a new benchmark for oncology care in the GCC.

A multidisciplinary team of specialists works collaboratively to provide tailored solutions that align with international standards while addressing regional healthcare challenges.

Dr. Michael Walsh, CEO of JHAH, described the launch as pivotal in the

organisation’s decade-long partnership with Johns Hopkins Medicine.

He emphasized that this collaboration integrates world-class expertise with Saudi Arabia’s cutting-edge healthcare advancements, creating a new standard for oncology care in the region

“The center demonstrates our shared commitment to transforming healthcare delivery and ensuring that patients across the GCC have access to world-class cancer care,” Walsh stated. Beyond its immediate impact on cancer treatment, the Oncology Center of Excellence positions the GCC as a leader in global medical innovation. By implementing proven medical protocols and leveraging advanced technologies developed by Johns Hopkins Medicine, the center enhances regional healthcare and contributes to global advancements in oncology.

NAFDAC issues warning on obsolete Insulin syringes

NIGERIA — The National Agency for Food and Drug Administration and Control (NAFDAC) has warned about the illegal circulation and marketing of a substandard and falsified medical product in Nigeria.

The product in question is the Knowit Insulin Syringe 40 IU 29G x 1/2, which poses significant risks to diabetic patients due to its potential for dosing errors.

This warning follows growing concerns from the Association of Community Pharmacists of Nigeria about the continued use of outdated 40 IU/ML insulin syringes.

Despite the widespread availability of safer, standardized 100 IU/ML alternatives, these older syringes remain in circulation.

Previously, 40 IU/ML syringes were

approved for use when both animal and human insulins were available. They were beneficial for administering Lente animal insulins, which were offered in two different concentrations.

However, with the shift toward human insulins, which are now uniformly standardized at 100 IU/ML, the 40 IU/ML syringes have become obsolete.

In their statement, NAFDAC clarified that these syringes are no longer registered for use, and their continued distribution can lead to serious dosing errors.

The agency’s statement highlights that using a 40 IU/ML syringe for administering 100 IU/ML insulin significantly increases the risk of miscalculation.

Most patients would find it

challenging to accurately adjust the dose, which can result in either an overdose or an insufficient dose.

Both scenarios carry potentially lifethreatening consequences, especially for individuals who depend on precise insulin administration to manage their blood sugar levels.

NAFDAC has since directed all zonal directors and state coordinators to intensify surveillance measures by identifying and removing any falsified Knowit Insulin Syringe stocks from circulation.

Furthermore, the agency has urged all importers, distributors, retailers, healthcare professionals, and caregivers to exercise heightened vigilance and refrain from importing, distributing, and selling the outdated product.

Emcure Pharmaceuticals launches cutting-edge R&D Centre in Ahmedabad, Gujarat

INDIA — Indian multinational pharmaceutical company Emcure Pharmaceuticals has inaugurated a cutting-edge formulation research and development (R&D) centre in Ahmedabad, Gujarat.

This new facility, named the Emcure Research Centre (ERC), is designed to advance the company’s efforts in creating innovative drug delivery systems and further solidify its position as a leader in the pharmaceutical industry.

The ERC strategically focuses on developing complex formulations, including sustained-release drugs, liposomal injections, and advanced dermal therapies.

Equipped with state-of-the-art laboratories and specialized equipment, the centre can handle various dosage forms and ensure that it covers the entire pharmaceutical development process.

This includes everything from initial pre-formulation studies to largescale production, all while adhering to stringent global regulatory standards.

The facility will employ 350 skilled professionals, comprising doctorate, postgraduate, and graduate specialists in pharmaceutical sciences, bioengineering, analytical chemistry, pharmacovigilance, and regulatory affairs.

These experts will collaborate to develop novel formulations, enhance drug bioavailability, and design patientcentric delivery solutions.

Their research will span multiple dosage forms, including oral solids, inhalers, injectables, topical and transdermal formulations, and novel drug delivery systems.

The launch of the ERC aligns with Emcure’s broader strategic initiatives,

which aim to drive innovation and expand its therapeutic offerings.

In October 2024, the company announced the creation of Emcutix Biopharmaceuticals, a wholly owned subsidiary dedicated to the dermatology sector.

Emcure Pharmaceuticals has a strong track record of collaborating with other industry leaders to enhance access to essential medicines. In April 2021, the company entered into a voluntary licensing agreement with MSD to supply the oral COVID-19 medication molnupiravir in India.

This initiative also involved other prominent Indian pharmaceutical companies, including Cipla, Dr. Reddy’s Laboratories, Hetero Labs, and Sun Pharmaceutical Industries, to ensure the drug’s wider availability.

AKUH launches specialized clinic for cholesterol disorders in Nairobi

KENYA — The Aga Khan University Hospital (AKUH) in Nairobi has launched a dedicated clinic for managing cholesterol (lipid) disorders to combat the rising burden of heart diseases in Kenya.

The launch event was attended by prominent figures, including Dr. Bernard Samia, President of the Kenya Cardiac Society (KCS), Rashid Khalani, CEO of AKUH, and Dr. Mzee Ngunga, the clinic’s Lead Interventional Cardiologist.

This specialized clinic is the first of its kind in Kenya and is part of a broader strategy to address the growing prevalence of heart disorders linked to lifestyle changes, such as dietary shifts and reduced physical activity.

The Lipid Disorders Clinic is staffed by a multidisciplinary team comprising

cardiologists, family physicians, nutritionists, specialist nurses, and pathologists.

This collaborative approach ensures that patients receive comprehensive and personalized care.

The clinic offers a range of services, including detailed cholesterol assessments, genetic testing to identify underlying lipid abnormalities, and tailored management plans developed by experienced healthcare professionals.

Patients are also provided with dietary advice and education on maintaining healthy cholesterol levels, empowering them to take proactive steps to manage their health.

Lipid disorder clinics are distinct from general cardiology clinics in their approach to identifying the root causes

of lipid imbalances and developing longterm monitoring plans.

This specialized care is crucial in reducing the incidence of heart attacks and strokes caused by blocked arteries, eventually improving life expectancy without the need for complex medications typically prescribed for heart attack survivors.

With services available at multiple locations, including the main hospital in Parklands, Valley Arcade Medical Centre, Karen Specialty and Executive Clinic, Peponi Specialty and Executive Clinic, and Capital Medical Centre, access to specialized lipid management is now more accessible to a wider population.

JOOTRH elevated to National Referral Hospital status

KENYA — The Jaramogi Oginga Odinga Teaching and Referral Hospital (JOOTRH) has officially been elevated to a National Referral Hospital and designated as a State Corporation.

The hospital joins Kenya’s top-tier public hospitals including Kenyatta National Hospital (KNH), Moi Teaching and Referral Hospital (MTRH), and Kenyatta University Teaching, Referral, and Research Hospital (KUTRRH).

This upgrade, following JOOTRH’s Level 6 classification in September 2024, enhances its mandate as a national center for specialized healthcare.

The new status enables the facility to manage more complex referrals across the region and expand its reach beyond Kisumu County.

JOOTRH CEO, Dr. Richard Lesiyampe, said the elevation marks a turning point in the hospital’s growth.

He highlighted improved staff welfare as one of the key benefits, including better compensation, career progression, and the conversion of casual and contract jobs into permanent and pensionable roles.

The move is expected to boost morale among long-serving staff, many of whom have worked under limited resources. It also paves the way for recruitment of additional personnel to meet growing demand, ensuring better service delivery and reduced workloads.

In a bid to improve healthcare access, JOOTRH plans to establish satellite clinics at grassroots levels. These outreach centers will bring services closer to the community and minimize the need for patients to travel long distances for specialized care.

With its new status, the hospital is set to introduce advanced medical services such as cardiac transplants and radiotherapy—essential treatments not previously available in the region.

Staff will also benefit from specialized training programs to enhance skills and keep up with modern medical innovations.

The elevation of JOOTRH signals a significant investment in Kenya’s public health infrastructure and a commitment to equitable, quality healthcare across the country.

APPOINTMENTS UPDATE

Aster DM Healthcare names Jacob Jacob as

Group CHRO

UAE — Aster DM Healthcare has appointed Mr. Jacob Jacob as the Group Chief Human Resources Officer to enhance its people excellence strategy, cultivate a high-performance culture, and provide an exceptional employee experience.

In his new role, Jacob will oversee all aspects of human resources, including talent acquisition, performance management, succession planning, leadership development, and organizational transformation across

Aster DM Healthcare’s operations in the GCC.

His leadership will be instrumental in aligning the company’s HR strategies with its broader vision, fostering a culture of innovation, and striving for excellence in all areas of operations.

Jacob will report directly to Ms. Alisha Moopen, Managing Director and Group CEO of Aster DM Healthcare, and will lead the full range of HR functions within the group.

With nearly three decades of experience, Jacob brings a wealth of expertise from leadership roles in various industries, including healthcare, real estate, aviation, and retail.

He has received several prestigious awards, including the Asia HRD Award and the HR Leadership Award, which highlight his exceptional record in human resources.

Nomfundo Vilakazi

Promoted to HR Director at Dis-Chem

SOUTH AFRICA — Dis-Chem,

South Africa’s second-largest retail pharmacy chain with 165 stores, has appointed Nomfundo Vilakazi as its new Human Resources Director.

Vilakazi’s promotion follows a successful five-year tenure at Dis-Chem, where she held various leadership roles, most recently serving as the Head of HR Centres of Excellence (COE).

In this position, she led initiatives that enhanced talent management, improved employee engagement, and introduced innovative, people-focused systems. Her efforts significantly boosted operational efficiency and strengthened the company’s HR strategies.

Vilakazi’s appointment is transformative for Dis-Chem, as the company evolves into an integrated healthcare partner and retailer.

She is expected to lead efforts to build a culture of inclusivity, agility, and innovation, ensuring that the organization remains competitive and aligned with its strategic goals.

With a career spanning multiple industries, including retail, pharmaceuticals, aviation, FMCG, and parastatals, Vilakazi brings a wealth of diverse experience to her new role.

Her proven track record includes driving efficiency through HR digitization, cultivating organizational culture, and implementing effective talent management strategies. These accomplishments make her a dynamic and experienced leader ready to elevate Dis-Chem’s HR function.

CEPI appoints Dr. Amadou Alpha Sall to Lead vaccine manufacturing and supply chain

ETHIOPIA - The Coalition for Epidemic Preparedness Innovations (CEPI) has appointed Dr. Amadou Alpha Sall as its new Executive Director of Manufacturing and Supply Chain, marking a significant move to strengthen global and African vaccine access.

Dr. Sall, formerly CEO of Senegal’s Institut Pasteur of Dakar (IPD), brings extensive experience in vaccine manufacturing and leadership.

At CEPI, he will oversee efforts to enhance vaccine production capacity

in underserved regions, streamline supply chains, and implement innovative technologies to improve speed, scale, and access to vaccines during health emergencies.

His appointment aligns with Africa’s broader goal to reduce dependency on external vaccine sources and build local production capacity.

Dr. Jean Kaseya, Director General of Africa CDC, praised Dr. Sall’s track record and highlighted his potential to boost Africa’s local health commodity manufacturing efforts.

The announcement follows a May 2024 Memorandum of Understanding between CEPI and Africa CDC to expand collaboration on epidemic and pandemic preparedness across the continent.

CEPI’s “100 Days Mission,” a key goal of its 2022–2026 strategy, aims to develop safe and effective vaccines within 100 days of identifying new health threats—an effort Dr. Sall’s expertise is expected to accelerate.

Boehringer Ingelheim appoints Abdallah Hamed to Lead SAGEA Region

SAUDI ARABIA — Boehringer Ingelheim has appointed Abdallah Hamed as the General Manager and Head of Human Pharmaceuticals for Saudi Arabia, the Gulf, and East Africa (SAGEA).

In his new role, Hamed will lead strategic growth efforts across several critical healthcare sectors, including stroke, cardio-renal metabolic conditions, idiopathic pulmonary fibrosis, and rare diseases such as generalized pustular psoriasis.

His focus will be on advancing the company’s regional priorities, fostering innovation, and expanding market reach to deliver Boehringer Ingelheim’s leading healthcare solutions.

In addition to driving business objectives, Hamed aims to strengthen the company’s partnerships with regional governments and key healthcare stakeholders, ensuring that patients continue to benefit from Boehringer Ingelheim’s diverse range of medications and treatments.

His appointment highlights Boehringer Ingelheim’s commitment to enhancing its relationships with local stakeholders and improving patient access across the SAGEA region.

Hamed has over two decades of experience in the pharmaceutical industry, during which he has held significant leadership positions throughout the Middle East.

Hamed holds a bachelor’s degree in pharmacy from the Applied Science University in Jordan. He brings with him a comprehensive understanding of market dynamics and proven expertise in sales, market access, and business unit management.

RFH Healthcare names Dr. Batul M. Fankupi as Acting CEO

KENYA — RFH Healthcare has appointed Dr. Batul M. Fankupi, MD, MBA (HCM), as the new Acting Chief Executive Officer, effective March 2025.

In an official statement, the hospital highlighted that Dr. Fankupi’s career embodies an exemplary mix of clinical expertise and strategic vision, making her the ideal candidate to steer the institution into its next growth phase.

She will now succeed Dr. Nicholas Kaweru, who has been serving as the Acting CEO and Director of Human Resources since he joined RFH Healthcare in 2022.

In her new role as Acting CEO, Dr. Fankupi will further drive the transformation of RFH Healthcare by leveraging her extensive experience in clinical and administrative domains.

Dr. Fankupi is a staunch advocate for innovative practices and disruptive technology, believing that these elements are key to sustaining long-term growth and operational excellence.

By championing collaborative teamwork and disciplined execution, she is expected to lead the organization toward a future where patient care and innovation go hand in hand.

Over the course of her career, spanning more than nine years, Dr. Fankupi has demonstrated a remarkable ability to integrate clinical insight with robust managerial strategies.

Marketing Veteran Karan Khanna joins Sidra Healthcare

UAE — Sidra Healthcare, a prominent healthcare provider in the UAE, has appointed Karan Khanna as its new Director of Marketing.

This appointment comes as the organization aims to strengthen its position as one of the leading healthcare providers in the UAE, known for delivering world-class medical services.

In his new role, Karan Khanna will lead initiatives in brand development, digital marketing, and the establishment of strategic partnerships, while also overseeing customer engagement initiatives.

Each of these areas is crucial for reinforcing Sidra Healthcare’s reputation as a trusted and innovative provider of healthcare solutions.

By integrating modern marketing strategies with deep industry insights, Khanna is expected to drive significant strategic growth for the company. He brings over 12 years of extensive experience in marketing and brand management.

Khanna has an impressive track record that includes key roles at renowned organizations such as Al Sagr National Insurance Co. and Sehteq TPA.

At these companies, he played a pivotal role in shaping innovative marketing strategies and enhancing brand positioning, which earned him recognition as a leader in the field.

His deep understanding of both the healthcare and insurance sectors further enhances his ability to contribute meaningfully to Sidra Healthcare’s ongoing evolution.

Medical Laboratories in Kenya

The Pathology Department at Aga Khan University Hospital provides state-of-the-art laboratory medicine services for the population of the East African region. The services include Clinical Chemistry, Haematology/Blood Transfusion, Histopathology / Cytology, Microbiology and Molecular Biology.

Ampath is a partnership between Moi University, Moi Teaching and Referral Hospital, and the AMPATH Consortium that conducts significant medical research.

Cerba Lancet Kenya offers comprehensive pathology services, corporate wellness programs, occupational health services, veterinary diagnostics, and clinical research.

Diamond-path Laboratory is a provider of diagnostic laboratory testing, information and services. Their test menu scope lies in Hematology, Biochemistry, Special chemistry, Microbiology, Molecular biology and Histopathology & Cytopathology.

KEMRI is the national body responsible for carrying out health research in Kenya, providing advice on various aspects of healthcare and delivery.

Agakhan University Hospital Nairobi

Ampath Kenya Eldoret

Cerba Lancet Kenya, Nairobi, Kenya

Diamond - path Laboratory Nairobi

Kenya Medical Research Institute (KEMRI) Nairobi

It’s the leading public referral hospital in Kenya and E. Africa region.

With more than 10 specialized laboratories, KNH offers laboratory tests ranging from basic to the esoteric.

Metropolis Laboratories Africa offers a comprehensive range of clinical laboratory tests and profiles. These tests and profiles are used for prediction, early detection, diagnostic screening, confirmation and/or disease monitoring.

Millennia Healthcare Laboratory Services is a department within Millennia Healthcare that provides various diagnostic tests through its laboratory services.

PathCare Kenya is one of the leading pathology practices in the country, offering services in clinical chemistry, endocrinology, haematology, microbiology, histology, cytology, serology, and genetics.

Quest Laboratories offers various services ranging from haematology to genetics and newborn screening.

Kenyatta National Hospital

Metropolis Laboratories Africa Nairobi

Millennia Healthcare Laboratory Services Nairobi

PathCare Kenya Nairobi Quest Laboratories Nairobi

LIONS SIGHTFIRST EYE HOSPITAL

Restoring Sight and Hope: The Holistic Care Mission

BY ALPHONSE OKOTH

Lions SightFirst Eye Hospital (LSEH) has been a beacon of hope in the management of eye disease in Kenya since its establishment in 1997. Conceived by Lions Clubs International, the hospital emerged from a series of mobile eye camps to address preventable blindness in Kenya. Today, the institution stands as a hub for comprehensive ophthalmological care, pioneering treatments, and holistic health services.

In an interview with Healthcare Middle East & Africa magazine, Dr. Rizwana Peerbhoy, the General Manager of LSEH, gives insight into the hospital’s journey since its inception, its services, milestones, and challenges.

A VISION TO SERVE

The genesis of LSEH was rooted in the need for continuity in patient care. Mobile camps, while impactful, lacked follow-up mechanisms for complex conditions such as glaucoma and retinal diseases. “These medical camps served their purpose but left a significant gap in ongoing treatment,” she explains. “We saw many patients who required regular monitoring and care that could not be offered through a transient setup. That realization led to the establishment of a permanent facility. Thus, the LSEH, a super specialty in eye care”

Dr. Peerbhoy reflects on the hospital’s mission: “We wanted to create a temple of healthcare service where people could receive immediate treatment and follow-up care, ensuring long-term health outcomes. It is about more than just addressing immediate need; it is about fostering sustained well-being.” This vision has become the cornerstone of LSEH’s operations, enabling it to transform lives of many people across the region.

EXPANDING SERVICES FOR COMPREHENSIVE CARE

Initially focused on cataract surgeries, LSEH has evolved into a multidisciplinary facility. “Our aim has always been to meet the diverse needs of our patients,” says Dr. Peerbhoy. To address this, the hospital introduced retina specialists to treat conditions such as retinopathy of prematurity. “Premature babies often face retinal issues that, if untreated, could severely impair their vision for life,” she explains. In 2009, the hospital further expanded its services by developing the region’s (East and Central Africa) only cornea bank. “The cornea bank is a game-changer,” says Dr. Peerbhoy. “We can harvest corneas within a six-to-eight-hour window after donor consent and preserve them for up to two weeks. This gives us a critical window to restore sight to those in need.” However, the demand remains high, with over 3,000 patients awaiting transplants.

“The waiting list is a sobering reminder of how much work still needs to be done,” she adds. “We continuously strive to encourage more donor participation to bridge this gap and give the gift of sight to as many people as possible.”

Beyond ophthalmology, the hospital’s services extend to diabetes management, Ear Nose and Throat infections (ENT), dental care, and wound treatment. “We later realized that many of our patients with eye problems also had undiagnosed diabetes,” shares Dr. Peerbhoy. “This discovery prompted us to create a diabetes unit, Diabetes Care Center (DCC), that manages the condition and addresses its complications, especially those affecting vision.”

Our DCC unit has since evolved into a multidisciplinary center. “Our team does not just treat diabetes but educates patients about lifestyle changes,” she explains. Simple interventions, such as advising patients on a balanced diet or incorporating more physical exercise into their routines, have made a world of difference.”

Additionally, the unit’s efforts to prevent diabetes-related complications such as foot ulcers have been transformative. “In the past year alone, we have saved dozens of patients from undergoing amputations,” Dr. Peerbhoy notes proudly. By addressing wounds early and providing the necessary care, we preserve not just limbs but lives.”

THE EYE UNIT: A COMPREHENSIVE APPROACH TO EYE CARE

Dr. Solomon Asacha, a senior cataract surgeon at the hospital for two decades, explains the hospital’s all-inclusive approach. “We perform comprehensive eye examinations to diagnose a variety of conditions such as cataracts, glaucoma, and diabetic retinopathy,” he shares. “Our goal is to provide curative care and preventive and rehabilitative services.”

Cataracts, a leading cause of reversible blindness, form a significant portion of the hospital’s caseload. “Cataracts often result from ageing, but we also see cases linked to diabetes, inflammation, or trauma,” says Dr Asacha. “Through advanced surgical techniques, we restore sight and transform lives. It is incredibly fulfilling to see patients regain their independence and confidence.”

Glaucoma, on the other hand, presents a greater challenge due to its irreversible nature. “We focus on early detection and management,” Dr. Asacha explains. “This includes family screenings to identify genetic predispositions and advanced treatments to prevent optic nerve damage.”

Kenya’s tropical climate contributes to a high prevalence of allergies and other eye-related conditions. “Environmental factors play a big role,” notes Dr. Asacha. “We see many

cases of allergic conjunctivitis and infections caused by microorganisms.”

Another concern is the widespread use of digital devices, which has increased computer vision syndrome. “During the COVID-19 pandemic, screen time skyrocketed,” he explains. “We now advise patients on proper screen usage, provide lubricating eye drops, and recommend blue-light filtering glasses to mitigate the effects.”

ADVANCED TECHNOLOGY AND SERVICES

Lions SightFirst Eye Hospital prides itself on being a one-stop center for eye care. “We have state-of-the-art equipment for diagnostics and treatment,” says Dr. Peerbhoy. “From laser technology to specialized imaging, we ensure our patients receive the best care without needing to leave the country.”

The hospital also runs outreach programs to screen schoolchildren and rural communities. “In schools, we have identified many cases of refractive errors and provided corrective lenses,” says Dr. Rizwana. Children with undiagnosed vision problems often struggle in class, and it is immensely rewarding to see their academic performance and confidence improve after receiving the right support.”

Additionally, the hospital’s rural outreach programs have been instrumental in detecting severe eye conditions in adults. “We have encountered cases of advanced cataracts and glaucoma during these visits,” she adds. By bringing services directly to these communities, we help restore human sight and raise awareness about the importance of regular eye checkups.

The hospital’s emphasis on rehabilitation ensures that even patients with irreversible conditions can lead fulfilling lives. “We counsel and teach patients to use assistive devices

SOME OF THE PATIENTS TO UNDERGO EYE CARE SURGERY

like white canes,” says Dr. Peerbhoy. “This holistic approach restores not just sight but dignity and independence.”

COMMITMENT TO ACCESSIBILITY AND OUTREACH

Accessibility is central to the hospital’s mission. Recognizing rural populations’ challenges, Lions SightFirst Eye Hospital conducts monthly follow-up visits to patients treated at its mobile camps and operates satellite clinics. The hospital’s satellite clinics are Village Market, M. P Shah Hospital, Dheg Towers at Eastleigh, and M. P. Shah Social League clinic along Temple Road in Nairobi’s Central Business District.

The facility at Kisumu is LSEH’s major upcoming center. “We have expanded to cater to underserved populations in the Western Kenya region and neighboring countries,” says Dr. Peerbhoy. “This will allow us to reach more people who would otherwise struggle to access care.” Additionally, the hospital collaborates with partners such as Johnson & Johnson to conduct school screening programs, identifying and addressing vision problems in children early.

INVESTING IN TRAINING AND RESEARCH

LSEH has launched several initiatives to train and retain talent to address Kenya’s critical shortage of specialized ophthalmologists. “Training is the backbone of sustainable healthcare,” emphasizes Dr. Rizwana. The hospital actively recruits international experts who provide care and mentor local clinicians. “We aim to create a generation of highly skilled professionals who can address the unique challenges of eye care in Africa,” she adds.

Recently certified as a research institute, the hospital is pushing the boundaries of innovation. “We are exploring

OUR FOUNDERS SAW HEALTHCARE AS MORE THAN TREATING ILLNESSES; IT WAS ABOUT CARING FOR THE WHOLE PERSON—BODY, MIND AND SPIRIT.

Dr. Rizwana Peerbhoy - GM, LSEH

treatments specifically tailored to African populations,” notes Dr. Peerbhoy. This includes research on environmental factors and lifestyle conditions disproportionately affecting the region.

Internal growth is also a focus. One inspiring example is a driver who transitioned to become a certified cornea harvester.

“We believe in nurturing talent at all levels,” she says. “Everyone has the potential to make meaningful contributions, and we’re here to support that journey.”

The hospital’s training programs extend beyond medical professionals. “ We do engage community health workers and local leaders to amplify our impact,” explains Dr. Peerbhoy. The hospital ensures that early detection and intervention become a grassroots effort by equipping communities with knowledge. “Our vision is not just to treat patients but to empower communities to take charge of their eye health,” she adds.

THE DENTAL LABORATORY AT LSEH

DR. RIZWANA PEERBHOY - GM, LION SIGHTFIRTS EYE HOSPITAL

CHALLENGES AND RESILIENCE

While the hospital’s impact is undeniable, it faces challenges such as delayed insurance payments and high equipment costs. As a welfare organization, Lions Eye Hospital relies on a Robin Hood model: patients who can afford care subsidize services for those who cannot. “This approach ensures no one is turned away,”

Dr. Peerbhoy emphasizes.

Late diagnosis is another issue. “Many patients seek help only when it is too late,” laments Dr Asacha. “We are working to raise awareness about the importance of regular eye checkups, especially for high-risk groups like diabetics.”

Government regulations, though stringent, are seen as constructive. “The policies are designed to protect patients and promote quality

PATIENT BEING CARED FOR AT LSEH’S FOOT & WOUND DEPT

IN NUMBERS

PATIENTS TREATED BY LSEH SINCE INCEPTION 5M

care,” says Dr. Peerbhoy. The hospital’s collaboration with county governments further enhances its outreach, with local facilities often providing space and security for mobile camps.

A HOLISTIC APPROACH TO HEALTHCARE

LSEH’s holistic care philosophy sets it apart. By integrating services like nutrition counseling, diabetes management, and rehabilitation, the hospital treats patients comprehensively, addressing underlying causes and improving overall wellbeing. This approach resonates with its partners, including global organizations such as Bayer and Novartis.

LIONS SIGHTFIRST EYE HOSPITAL CONDUCTS MONTHLY FOLLOW-UP VISITS TO PATIENTS TREATED AT ITS MOBILE CAMPS AND OPERATES SATELLITE CLINICS.

LOOKING AHEAD

While expanding training programs, plans are underway to introduce oncology and kidney services at our upcoming to further intensify our services. “LSEH’s goal is to be the best in Africa, providing not just treatment but also education and research,” Dr. Peerbhoy states.

LSEH’s journey is a testament to the power of compassion, innovation, and community collaboration. By restoring sight and offering holistic care, it not only transforms individual lives but also uplifts families and communities. For Dr. Peerbhoy, the mission is clear: “We aim to give people the gift of sight and a dignified life.”

A DEADLY ECHO: The Return of Marburg to East Africa MARBURG VIRUS DISEASE (MVD) DISEASE FOCUS

BY VINCENT MORANGA

Even before we could contain the Mpox virus, which the Africa Centers for Disease Control and Prevention (Africa CDC) reports has led to over 77,800 cases and 1,321 deaths by the end of 2024, East Africa now faces another threat: the Marburg virus. This virus has gained traction due to its resurgence in Tanzania, rekindling memories of the COVID-19 pandemic we faced a few years ago. During that time, Tanzania faced criticism for not sharing infection data and overlooking preventive measures, raising concerns about the country’s preparedness to manage this current outbreak.

A CLOSE RELATIVE OF EBOLA

First identified in 1967, the Marburg virus—although less wellknown than Ebola—belongs to the same family of viruses and has caused some of the most severe viral outbreaks in history. Marburg virus disease (MVD) is classified as a rare but highly lethal viral haemorrhagic fever, with case fatality

rates reaching as high as 88%, according to the World Health Organization (WHO). However, timely and effective medical care can significantly reduce this rate.

Unlike many respiratory viruses, MVD is not easily transmissible. Historically, outbreaks of MVD have been sporadic and are often linked to zoonotic transmission from animals to humans. However, the WHO reported that in 2008, two independent cases of human infection occurred in travellers who visited a cave inhabited by colonies of Rousettus aegyptiacus bats in Uganda.

Once humans contract the virus through direct exposure, it can then spread from person to person through direct contact with bodily fluids such as blood, saliva, urine, vomit, and other secretions from infected individuals. Contaminated surfaces and materials can also serve as pathways for transmission.

With an incubation period varying from 2 to 21 days, individuals infected with the Marburg virus commonly experience a range of symptoms, which include fever, chills,

headaches, muscle pain, rashes, chest pain, sore throats, diarrhoea, vomiting, stomach pain, and, in severe cases, unexplained bleeding or bruising.

TANZANIA MARBURG ALERT

Its recent emergence in Tanzania has raised eyebrows, with the WHO issuing an alert on January 15, 2024, and Tanzanian authorities officially declaring the outbreak on January 20, 2024. As of January 28, the Ministry of Health had confirmed two cases of MVD, both of which resulted in fatalities. Additionally, there have been eight probable deaths, 64 suspected cases, and 281 contacts being monitored for symptoms of the disease in the Kagera region. This current outbreak follows a previous incident in March 2023, whereby nine cases and six fatalities were reported.

WITH AN INCUBATION PERIOD VARYING FROM 2 TO 21 DAYS, INDIVIDUALS INFECTED WITH THE MARBURG VIRUS COMMONLY EXPERIENCE A RANGE OF SYMPTOMS, WHICH INCLUDE FEVER, CHILLS, ETC.

Due to Kagera’s cross-border movement and trade, the WHO has warned about the high risk of spreading disease to neighbouring countries, including Rwanda, Uganda, and Burundi. Although no cases have been reported in Kenya, the Kenyan government has activated its disease response systems at all entry points, particularly in counties that border Tanzania. Some of these measures include enhancing surveillance and screening of travellers, increasing laboratory testing capacity, public risk communication, and strengthening infection prevention and control protocols.

RWANDA’S MARBURG EXPERIENCE

Tanzania is not the first East African country to encounter a Marburg outbreak along its borders. Rwanda has faced similar challenges, with the Rwandan Ministry of Health confirming the country’s first outbreak of Marburg virus disease on September 27, 2024. Within just three days, by September 30, the number of confirmed cases surged to 29, with 10 reported fatalities and over 297 contacts, including healthcare workers, placed under close monitoring.

During the epidemic at two facilities in Kigali, 66 individuals became ill, and 15 fatalities were recorded. Investigations into the outbreak’s

origin indicated that fruit bats in a mining cave were responsible, highlighting the zoonotic nature of the virus. In response, the Centers for Disease Control and Prevention (CDC) and the WHO quickly provided technical assistance and support for infection prevention measures. Their coordinated efforts were effective, and after 42 consecutive days without new cases, Rwanda declared the outbreak over on December 20, 2024.

INSIDE RWANDA’S MARBURG RESPONSE

Before the virus was effectively controlled in 2024, Rwanda implemented several measures to curb its spread. A significant initiative was the establishment of a pool of Rapidly Deployable Experts (RDE) through the East African Community (EAC) Secretariat. The WHO and other partners funded this effort to ensure that experts could be swiftly dispatched to affected areas. Moreover, the Secretariat played a vital role in enhancing risk and crisis communication and set up 43 Water, Sanitation, and Hygiene (WASH) facilities along border areas.

The Secretariat also improved laboratory testing capacity in the Partner States by providing diagnostic PCR kits for the Marburg and Monkeypox viruses. This enabled the deployment

of mobile laboratories in key locations and the donation of essential laboratory equipment, such as sequencers. These comprehensive actions are crucial in combating the outbreak and safeguarding public health in the region.

Another important player was Gilead Sciences, Inc., which, in October 2024, with support from Rwanda’s Ministry of Health, donated 5,100 vials of remdesivir to combat the Marburg virus disease (MVD) outbreak in Rwanda. Remdesivir, which was recognised during the 2014-2015 Ebola outbreak and tested in the 2018 Ebola outbreak in the Democratic Republic of Congo, was provided as an emergency measure since there is no approved cure for MVD.

LESSONS FROM RWANDA

Drawing on Rwanda’s collaborative experiences, the Tanzanian government is working closely with the WHO and other partners to obtain technical guidance and logistical support for implementing essential outbreak management measures. These measures include disease surveillance and public awareness programmes targeting communities and healthcare personnel, concentrating on the prevention and symptoms of the Marburg virus to avert further spread.

The Africa CDC has also assembled a team of

twelve public health experts, comprising epidemiologists, risk communication specialists, infection prevention and control (IPC) experts, and laboratory professionals, to provide onthe-ground assistance with surveillance, diagnostics, IPC, and community engagement. It has also allocated US$2 million to enhance immediate actions, including deploying public health specialists, increasing diagnostic capacities by procuring testing kits and equipment, and improving case management by providing training and resources to healthcare facilities.

The fight against the Marburg virus presents a global concern due to its potential for rapid international spread. Organisations such as the CDC and WHO, along with African ministries of health and local NGOs, are collaborating to enhance public health capacities. Their efforts focus on improving disease surveillance, laboratory capabilities, workforce training, and border health systems, while also strengthening outbreak response measures, including case management, infection control, and safe burial practices.

CURRENT APPROACHES TO MARBURG

According to the WHO, supportive treatment remains the primary approach for managing Marburg haemorrhagic fever. This involves maintaining hydration to combat fluid loss, balancing electrolytes to support organ function, and managing haemorrhagic complications to control bleeding. Strict barrier nursing techniques are also essential when caring for patients

THE INCOMPLETE UNDERSTANDING OF THESE DYNAMICS COMPLICATES THE DEVELOPMENT OF TARGETED INTERVENTIONS BEYOND GENERAL PRECAUTIONS.

suspected or confirmed to have Marburg haemorrhagic fever. This includes utilising personal protective equipment (PPE) such as gowns, gloves, masks, and eye protection to prevent direct contact and ensure safety.

Preventive strategies against Marburg virus infection are still being developed, and understanding the precise transmission dynamics from wildlife to humans is an area of ongoing research. The incomplete understanding of these dynamics complicates the development of targeted interventions beyond general precautions. To minimise the risk of infection, avoid direct contact with bats and non-human primates, particularly those that appear sick or injured, and practise good hygiene, including the safe handling of bushmeat.

A PATH FORWARD

Progress in the fight against Marburg Virus Disease (MVD) offers hope for enhanced prevention and management; however, the disease presents significant challenges. One difficulty in diagnosing MVD is that its symptoms often overlap with those of other illnesses, such as malaria, typhoid fever, shigellosis, meningitis, and other viral haemorrhagic fevers. Therefore, accurate and timely diagnosis remains crucial.

The WHO has recommended several diagnostic tests to confirm Marburg Virus Disease (MVD) cases, which are vital for saving lives. These tests include the antibody-capture enzyme-linked immunosorbent assay (ELISA) for detecting antibodies, antigen-capture tests for identifying viral proteins, reverse transcription polymerase chain reaction (RT-PCR) for detecting the virus’s genetic material, electron microscopy, and virus isolation through cell culture.

Just like for Ebola, there are currently no vaccines or specific antiviral treatments for Marburg that have been approved for widespread use by regulatory bodies such as the FDA or WHO. Nevertheless, several promising vaccine candidates and therapeutic agents are in various stages of preclinical and clinical trials. These candidates comprise vaccines based on the vesicular stomatitis virus (VSV-MARV), Vaccinia Ankara (MVA-BN-Filo), and chimpanzee adenovirus (ChAd3). Developing these vaccines is essential for controlling outbreaks and safeguarding healthcare workers at higher risk.

THE RISE OF MEDICAL WEIGHT LOSS: Transforming Strategies for obesity management

BY YEGON HILLARY

The global prevalence of obesity has reached epidemic proportions, posing significant challenges to public health systems worldwide. As of 2022, according to the World Health Organization (WHO), over 2.5 billion adults (18 years or older) were classified as overweight, with approximately 890 million living with obesity. This equates to about 43% of adults being overweight, which shows an increase from 1990 when 25% of adults aged 18 years and above were overweight. In addition, according to the latest World Obesity Atlas 2023, the number of individuals in the overweight and obesity category is expected to reach 4 billion by 2035. This indicates that 1 in 5 women and 1 in 7 men will be living with obesity by 2030. Obesity rates have been skyrocketing across Africa, with one in five adults and one in 10 children were obese by the end of 2023 in 10 high-burden countries if urgent action is not taken. In 2019, Africa was home to 24% of the world’s overweight children under 5, and overweight and obesity rates among African children and adolescents aged 5-19 have doubled in the 16 years to 2022. For adults, overweight and

obesity nearly doubled in the 6 years to 2016.

To combat this crisis, African countries are implementing a multi-pronged approach combining policy initiatives, community awareness campaigns, healthcare system integration, and innovative treatment methods like pharmacotherapy. Key strategies include government regulations on food marketing and sugar content, fiscal policies taxing sugary drinks, mandatory nutrient labeling, promoting healthy foods for children, creating facilities for active transport and recreation, and reinforcing public health services. This comprehensive, evidence-based approach aims to transform obesity management in Africa and reverse the alarming rise in overweight and obesity across the continent

EVOLUTION OF WEIGHT MANAGEMENT STRATEGIES

Traditiona Approaches: Limitations and Challenges

Historically, weight loss efforts relied on conventional methods such as caloric restriction, exercise regimens, and behavioral counseling. These techniques focused on modifying

dietary habits, increasing physical activity, and addressing psychological factors contributing to weight gain. While foundational, these approaches often struggled to achieve sustainable, long-term weight loss due to individual adherence issues and metabolic resistance.

MEDICAL WEIGHT LOSS PROGRAMS: A MULTIFACETED APPROACH

Surgical Interventions: Gastric Bypass and Sleeve Gastrectomy

Surgical procedures like gastric bypass and sleeve gastrectomy alter the anatomy of the digestive system, leading to significant weight loss and improvements in metabolic health. These interventions are typically recommended for patients with severe obesity or obesity-related comorbidities.

Non-surgical options: Lifestyle modifications and pharmaceutical aids

Non-surgical interventions focus on behavioral modifications, including personalized diet and exercise plans, cognitivebehavioral therapy, and pharmaceutical aids such as GLP-1 receptor agonists. These medications, initially developed for managing type 2 diabetes, have shown promising results in facilitating weight loss by reducing appetite and improving satiety.

According to an article written and published by UCLA Health on patients who’ve undergone these procedures, these interventions have demonstrated effectiveness in promoting weight loss and supporting long-term lifestyle changes. The efficacy of these programs is not just clinical but also deeply personal, as seen in Jennifer’s and Kallista’s stories. Jennifer,

SINCE LAUNCHING, THEY HAVE SERVED OVER 16,000 PATIENTS AND PROVIDED STEADY, DIGNIFIED WORK TO MORE THAN 3,000 HEALTHCARE PROFESSIONALS.

who lost over 100 pounds post-gastric sleeve surgery, and Kallista, who shed 87 pounds, highlight the profound impact of comprehensive care and the importance of lifestyle changes in achieving sustainable weight loss.

EMERGING TRENDS IN WEIGHT LOSS

The recent trend of using diabetic drugs for weight loss reinforces a fundamental shift in pharmaceutical approaches to managing obesity and diabetes. This trend is primarily rooted in discovering that certain medications, notably GLP1 receptor agonists like Ozempic (semaglutide) and Wegovy, possess dual benefits.

Traditionally prescribed to enhance blood sugar control in type 2 diabetes, these drugs have demonstrated remarkable efficacy in facilitating weight loss. The FDA’s approval of Wegovy for weight loss in individuals with type 2 diabetes, high blood pressure, or high cholesterol signifies a pivotal moment in the pharmaceutical industry’s approach to weight management.

Understanding weight loss drugs like Ozempic and Wegovy involves a comprehensive examination of their mechanisms of action, efficacy, safety profiles, and patient experiences. These medications, administered via subcutaneous injection, have garnered attention for their ability to aid in weight loss and improve blood sugar control in adults with type 2 diabetes.

PHARMACEUTICAL INNOVATIONS IN WEIGHT MANAGEMENT

GLP-1 Receptor Agonists: Dual Benefits in obesity and diabetes management

GLP-1 receptor agonists like Ozempic (semaglutide) and Wegovy (semaglutide) have emerged as pivotal therapies in medical weight loss. These medications mimic the action of the incretin hormone GLP-1, which regulates glucose metabolism and appetite. Beyond their primary use in diabetes management, GLP-1 receptor agonists have demonstrated significant weight loss benefits in clinical trials, offering a novel approach to addressing obesity.

CLINICAL EFFICACY

Studies have shown that patients using GLP-1 receptor agonists can achieve substantial weight loss percentages, improving glycemic control and metabolic parameters. Ozempic, given once weekly, is lauded for its capacity to lower the risk of major cardiovascular events. In contrast, Wegovy’s dosage regimen starts at 0.25 mg weekly, gradually increasing to a maintenance dose of either 1.7 or 2.4 mg.

GLP-1 receptor agonists mimic the incretin hormone GLP-1, which reduces appetite and food intake and aids in weight loss. This mechanism not only helps manage diabetes by controlling blood sugar levels but also addresses obesity, a significant risk factor for type 2 diabetes. The profound impact of weight loss on diabetic patients’ health outcomes is evident, as it can improve blood sugar control, reduce the need for insulin therapy, and even lead to diabetes remission in some cases.

Case studies examining the effectiveness of drugs like Ozempic and Wegovy highlight their dual role in managing

obesity and diabetes. For instance, adults with type 2 diabetes who participated in a clinical trial for Wegovy experienced an average weight loss of 6.2% of their body weight compared to those who received a placebo. However, despite their transformative potential, it’s essential to recognize that these medications are not without side effects. Common issues include gastrointestinal symptoms, and when used alongside other diabetes treatments, they may increase the risk of hypoglycemia.

Overall, weight loss drugs like Ozempic and Wegovy have emerged as significant components of medical weight loss programs, offering a multifaceted approach to addressing obesity and diabetes. These medications exemplify the intersection between pharmacological interventions and holistic health management strategies by mimicking natural hormonal signals related to appetite control and blood sugar regulation.

SAFETY PROFILE

While generally well-tolerated, these medications may cause gastrointestinal side effects such as nausea and diarrhea, requiring careful patient monitoring and management. Despite

their efficacy, patient experiences with these drugs vary widely, with reported side effects ranging from nausea and vomiting to more severe conditions like stomach paralysis. Such adverse reactions stress the importance of patients discussing potential risks with their healthcare providers.

Reports from users detail a spectrum of experiences, from significant weight loss to debilitating side effects. For instance, Carey Yazeed’s account of her experience with Ozempic was initially featured in an article published on NBC News titled “What it’s like to take the blockbuster drugs Ozempic and Wegovy, from severe side effects to losing 50 pounds,” by Aria Bendix and Berkeley Lovelace Jr., described experiencing vomiting, fatigue, headaches, and severe stomach cramps that that left her incapacitated.

While extreme reactions like these are relatively rare, they highlight the challenges some individuals face when using these medications. Nevertheless, the popularity of Ozempic and Wegovy continues to soar, propelled by their weight loss effects and high-profile endorsements.

Despite the transformative potential of weight loss drugs in enabling activities previously hindered by obesity-related health issues, they are not without drawbacks. Alongside gastrointestinal problems like nausea and vomiting, users may struggle to sustain weight loss once they discontinue the medications, emphasizing the need for long-term management of obesity.

Ultimately, while some individuals find the benefits of weight loss outweigh the discomfort of side effects, others may find the adverse effects intolerable, leading them to discontinue the medications.

This emphasizes the nuanced nature of using weight loss drugs and the importance of individualized treatment approaches in addressing obesity as a chronic condition.

Success stories abound, with patients sharing transformative experiences of substantial weight loss and improved health outcomes. These narratives highlight the potentially life-changing benefits of weight loss drugs, especially for those struggling with obesity-related health issues.

ACCORDING TO RESEARCH AND MARKETS, THE GLOBAL WEIGHT LOSS MARKET

IS

PROJECTED

TO GROW FROM US$1.94 BILLION IN 2023 TO US$12.17 BILLION BY 2028, AT A CAGR OF 43.5%.

PHARMACEUTICAL ADVANCEMENTS IN WEIGHT MANAGEMENT

Pharmaceutical giants and biotech firms are redirecting their resources towards researching and developing advanced weight loss therapies, reflecting a strategic response to the escalating demand for effective weight management solutions. Recent examples include Oral Semaglutide, a daily pill, and Zepbound (Tirzepatide), an injectable developed by Eli Lilly, which has demonstrated remarkable efficacy in facilitating weight loss.

Additionally, notable developments such as Retatrutide and the combination drug CagriSema, both injectables in advanced clinical trials, and MariTide, undergoing study for its weight management potential, highlight the industry’s commitment to diversifying treatment options and addressing the complex challenge of obesity. Oral medications like Orforglipron and Amycretin are also in the pipeline, indicative of ongoing efforts to innovate within this sector.

FUTURE DIRECTIONS AND INNOVATIONS

Advancements in drug development: Oral formulations and beyond

Pharmaceutical research continues to innovate with new drug formulations and mechanisms of action aimed at enhancing efficacy and patient adherence. Drugs like Oral Semaglutide and Zepbound (Tirzepatide) offer promising alternatives with improved tolerability and ease of administration.

TECHNOLOGICAL INTEGRATION: PERSONALIZED MEDICINE AND DIGITAL HEALTH TOOLS

Integrating genomics, biotechnology, and artificial intelligence (AI) in medical weight loss programs holds promise for personalized treatment approaches. Digital health tools and AI-driven analytics enable healthcare providers to tailor interventions based on individual genetic, metabolic, and behavioral factors, optimizing outcomes and patient engagement.

The landscape of medical weight loss programs and pharmaceutical interventions appears poised for significant

CHILDREN IN AFRICA WITH OBESITY IN 2023 1 in 10 IN NUMBERS

transformation shortly. With a focus on personalized medicine, these programs are set to integrate cutting-edge advancements in genomics and biotechnology, revolutionizing weight management. Digital health tools and AI-driven analytics are expected to be pivotal in tailoring individual interventions, ensuring more effective outcomes.

Alongside these innovations, emerging treatments such as peptide-based therapies and gut microbiota modulators show promise in providing precise and individualized options for weight loss. As these interventions become more prevalent, societal attitudes towards obesity and beauty standards may shift significantly, necessitating adjustments in healthcare systems to address ethical considerations and ensure equitable access.

MARKET TRENDS AND ECONOMIC IMPLICATIONS

The pharmaceutical market is on the brink of a surge in new drugs emphasizing oral administration and reduced side effects, aiming to enhance patient adherence. Concurrently, research increasingly identifies obesity as a chronic neurometabolic disease, driving the development of targeted therapeutics that could revolutionize treatment efficacy.

Anticipated paradigm shifts indicate a growing understanding of obesity that integrates behavioral, genetic, and metabolic factors into treatment approaches, combining pharmacotherapy, surgery, and lifestyle modifications. While these advancements offer hope for medical weight loss, caution is warranted due to the complex nature of obesity and its treatment.

The global market for obesity drugs is poised for substantial growth, driven by increasing obesity rates and advancements in

pharmaceutical therapies. Market projections indicate significant investment and expansion in the pharmaceutical sector, with drugs such as Ozempic and Wegovy leading in both efficacy and sales.

According to a global market report on weight loss drugs done by Research and Markets, the global market is projected to grow from US$1.94 billion in 2023 to US$12.17 billion by 2028, at a CAGR of 43.5%. This growth is driven by the escalating obesity rates worldwide, with over 4 billion people estimated to be obese by 2035. The anticipated increase in the forecast period can be attributed to factors such as the increasing geriatric population, social media influence, fitness and wellness trends, cultural perceptions of beauty, and continued investments by the pharmaceutical industry.

Analysts estimate that by 2032, over 25% of obese Americans and 15% of overweight Americans will be receiving GLP-1-based obesity treatments, which are expected to account for over US$56 billion in sales by 2030.

Overall, the obesity drug market is poised to become a US$71 billion industry within the next decade, providing significant opportunities for pharmaceutical companies and addressing the substantial economic burden caused by the obesity epidemic. Companies like Eli Lilly and Novo Nordisk are leading the way in this expansion, with their stocks surging due to the success of drugs like Mounjaro, Zepbound, Ozempic, and Wegovy.

However, challenges such as pricing, competition, and side effects may impact valuations. Nevertheless, the demand for obesity drugs is on the rise, with new medicines demonstrating efficacy comparable to bariatric surgery and showing minor tolerability issues.

CONCLUSION

Medical weight loss programs are reshaping the fight against obesity, offering integrated solutions that combine pharmaceuticals, surgical options, and lifestyle interventions. Drugs like Ozempic and Wegovy exemplify how pharmacological advancements can address obesity while also managing diabetes. However, ongoing research and patient-specific treatment plans remain crucial to maximizing benefits and minimizing risks.

As the landscape of weight management continues to evolve, a holistic, patient-centered approach will be key to tackling the global obesity crisis effectively.

EYES ON THE FUTURE: AI’s Promise to Restore Sight in Africa

BY VINCENT MORANGA

Every five seconds, someone loses their vision, with the World Economic Forum (WEF) reporting that uncorrected refractive errors, glaucoma, and cataracts are among the most prevalent eye diseases and visual impairments in Africa. According to Seva, a global non-profit organisation focused on eye care, despite the widespread challenge of avoidable blindness, eye care services remain gravely understaffed within the already strained health systems across the continent.

In terms of numbers, the World Health Organisation (WHO) estimates that one in every six blind individuals worldwide resides in Africa, with an additional 26 million people facing varying levels of visual impairment. Cataracts are responsible for approximately 50% of avoidable blindness in Africa alone and can be treated with a straightforward, cost-effective 15-minute surgery. However, only 14% of those needing cataract surgery receive it, while more than 80% of individuals with short-sightedness receive no treatment.

A TREATABLE CONDITION, YET UNTREATED

According to World Economic Forum (WEF), over 30 million people undergo cataract surgery each year, making it one

of the most common and effective medical procedures for preventing avoidable blindness. However, limited access to trained eye care professionals, inadequate infrastructure, and high treatment costs contribute to a significant gap in eye care services. Consequently, many individuals with cataracts remain undiagnosed and untreated, leading to avoidable visual impairments and a decreased quality of life.

According to Dr. Solomon Asacha, a senior cataract surgeon at Lions SightFirst Eye Hospital, cataracts remain a major cause of reversible blindness in Kenya and constitute a significant portion of the patient caseload. For over two decades, the hospital has operated as a comprehensive eye care centre in Kenya and is the only hospital in East and Central Africa with a dedicated cornea bank.

Furthermore, the increased reliance on digital devices has led to a rise in computer vision syndrome. “During the COVID-19 pandemic, screen time soared,” Dr. Asacha explains. “We now advise patients on appropriate screen usage, provide lubricating eye drops, and recommend blue-light filtering glasses to help alleviate these effects.”

The growing prevalence of cataracts, glaucoma, and other vision-related disorders has led to an increased demand

for ophthalmic devices utilised in surgical procedures, diagnostics, and vision correction. In the Middle East and Africa, the need for filtering glasses, contact lenses, corneal topographers, refractive lasers, retinal cameras, and ophthalmic microscopes presents significant opportunities for major players such as Johnson & Johnson Vision Care, Alcon, and Carl Zeiss Meditec. According to ResearchAndMarkets, this market is projected to expand from US$2.18 billion in 2023 to US$3.03 billion by 2031, with a compound annual growth rate (CAGR) of 4.2%.

A GAME CHANGER FOR EYE CARE

Dr. Rizwana Peerbhoy, General Manager of Lions SightFirst Eye Hospital, a specialty clinic of Lions Eye Hospital, describes advancements such as cornea banks as “a game-changer.” Corneas harvested from donors can now be preserved for up to two weeks, offering opticians a critical window to restore sight for those in need. However, the demand for this service remains high, with over 3,000 patients currently awaiting transplants.

What if we could harness artificial intelligence (AI) to predict, prevent, and even reverse visual impairment outcomes with unprecedented accuracy? AI is becoming an essential tool for screening diabetic retinopathy, performing cataract surgeries, modelling 3D imaging, and managing patients. Its advancements in detecting

WORLD HEALTH ORGANISATION (WHO) ESTIMATES THAT ONE IN EVERY SIX BLIND INDIVIDUALS WORLDWIDE RESIDES IN AFRICA, WITH AN ADDITIONAL 26 MILLION PEOPLE FACING VARYING LEVELS OF VISUAL IMPAIRMENT.

and diagnosing visual impairments, enhancing patient management and monitoring, and expanding telehealth services could significantly improve access to care and outcomes.

AI-POWERED SOLUTIONS IN ACTION

One potential application of AI in modern eye care is the utilisation of AI-powered telemedicine platforms. Through smartphone applications or web-based services, patients can upload images of their eyes for analysis by AI algorithms. These algorithms can screen for common eye conditions, provide preliminary diagnoses, and monitor disease progression over time. This remote monitoring capability is particularly beneficial for patients with chronic eye diseases who require regular check-ups.

Peek Vision, a UK social enterprise, has effectively utilised AI in Africa with its Peek Acuity platform for visual acuity tests and early detection of eye conditions. Their Peek Retina smartphone attachment transforms phones into retinal imaging devices for precise diagnoses. Additionally, Peek Solutions employs AI to develop personalised treatment plans, enhancing patient adherence and health outcomes. These initiatives demonstrate AI’s positive impact on eye care and encourage further investment in the sector.

Although AI has been regarded as a futuristic concept, Altris AI’s innovative platform, which employs advanced optical coherence tomography (OCT) imaging technology, has played a critical role in assessing the risk of developing glaucoma. This condition can lead to blindness if not diagnosed and treated early. It is particularly crucial in Africa, where access to specialized eye care is often limited, as it supports healthcare professionals in making timely and informed decisions regarding patient treatment.

Mobile applications are revolutionising vision testing, particularly in remote or underserved areas where access to traditional eye care facilities may be limited. OptikosPrime has collaborated with Sightsavers and eye health stakeholders in Africa to enhance smartphone-based vision testing. Using advanced algorithms, the OptikosPrime app analyses phone images to assess users’ eyesight and provide results that closely resemble those obtained through evaluations conducted by trained optometrists or opticians.

Automated AI diagnostics can analyse retinal images to

AI IS INCREASINGLY SIGNIFICANT IN OPHTHALMOLOGY, WITH ALGORITHMS NOW CAPABLE OF ANALYSING AND INTERPRETING COMPLEX EYE SCANS WITH REMARKABLE ACCURACY.

detect early signs of diseases such as diabetic retinopathy, agerelated macular degeneration, and glaucoma. In Rwanda, the Rwanda Diabetes Association has partnered with Cybersight AI to equip four clinics with advanced AI screening cameras that utilise the latest Orbis tool to diagnose diabetic retinopathy (DR). This technology enables opticians to assess patients within minutes, thereby enhancing outcomes and satisfaction.

NAVIGATING THE CHALLENGES

While the benefits of AI in eye care are significant, several challenges and ethical considerations must be addressed. These include data privacy, algorithmic bias, and the collaboration between humans and machines. Strong protocols are essential

to protect patient data and ensure compliance with regulations. Additionally, AI algorithms should be trained on diverse datasets to prevent exacerbating healthcare disparities, particularly for the African population, ensuring equitable access to healthcare services.

Integrating AI into existing electronic health record (EHR) systems can be intricate, yet successful integration is essential for seamless operations. Collaboration between AI systems and human experts is vital for making accurate diagnoses and delivering patient-centred care. Eye care professionals must also be trained to effectively comprehend and interpret AI results, incorporating them into their clinical practice.

A GLIMPSE INTO THE FUTURE

The future of artificial intelligence (AI) in eye care is promising, with ongoing advancements anticipated to revolutionise the detection, monitoring, and treatment of eye conditions such as diabetic retinopathy and age-related macular degeneration (AMD). AI is increasingly significant in ophthalmology, with algorithms now capable of analysing and interpreting complex eye scans with remarkable accuracy. This technology aids physicians in predicting risks and personalising patient care.

Surgical innovations are at the forefront of advancements in eye care. Techniques such as laser-assisted cataract surgery and Minimally Invasive Glaucoma Surgery (MIGS) exemplify these developments. Laser-assisted cataract surgery reduces the need for stitches and accelerates recovery, resulting in a more comfortable treatment experience. Meanwhile, MIGS effectively lowers intraocular pressure with fewer

complications and quicker recovery times compared to traditional methods. The integration of robotic assistance in surgeries is also anticipated to enhance success rates and minimise the risks associated with eye operations.

Emerging technologies, such as predictive analytics and oculomics, are at the forefront of vision technology. Oculomics employs ophthalmic biomarkers to forecast systemic health conditions, while AI-driven predictive analytics can examine a patient’s medical history, lifestyle, imaging data, and genetic information to make informed predictions regarding their eye health.

Innovative technologies such as bionic eyes and artificial retinas are being developed to restore vision in blind patients by stimulating nerve cells to create visual perceptions. Additionally, 3D-printed digital contact lenses are emerging as another exciting frontier in eye care innovation. Virtual reality (VR) and augmented reality (AR) are also set to revolutionise eye care by enhancing diagnostic and therapeutic processes. Technologies such as VR-based vision therapy exercises and AR-enhanced eyewear promise personalised treatment experiences tailored to individual patients needs.

The future also encompasses portable and home-based devices that facilitate the monitoring and management of eye health for patients. Devices such as Peek Retina allow users to capture retinal images using their smartphones, thus enabling remote diagnosis and treatment. Similarly, the Netra device operates as a binocular-like headset that connects to an app for diagnosing refractive errors, streamlining eye exams and enhancing accessibility. HCMEA

WITH ONLY 70 MONTHS LEFT TO end AIDS why is the urgency missing?

BY BOBBY RAMAKANT - CNS

The global AIDS response is not only off-thetarget but also slipping by leaps and bounds in some countries or for some communities. All governments promised to end AIDS by 2030 by committing to the UN Sustainable Development Goals (SDGs) a decade back “where no one is left behind.”

Undeniably, a lot of progress took place in preventing new HIV infections and helping millions of those living with the virus lead a healthy life worldwide. But this progress is no excuse for complacency or must not be allowed to paralyse us in urgently addressing the acute need of scaling up people-centred and rights-based responses.

Despite having a range of evidence-based HIV prevention tools, the world saw 1.3 million new people getting diagnosed with HIV in 2023. This is over three times more new infections than what was promised: Leaders had pledged to reduce annual new infections to below 370,000 by 2025.

Despite having best of HIV treatment options to keep people with HIV healthy and well, over 630,000 people died of AIDS-related illnesses in 2023. Compared to 2010 when 1.3 million people died of AIDS-related illnesses, the rate has halved by 2023 -but the number of lost lives in 2023 is 2.5 times more than what our leaders promised to achieve by 2025 (that deaths due to AIDS-related illnesses by 2025 should be less than 250,000).

ACUTE URGENCY FOR ACCELERATING RIGHTSBASED AIDS RESPONSE

“Every new HIV infection or a death due to AIDS-related illness is a grim reminder that we could have done better to prevent

HIV or on treatment, care and support. It is high time for accountability, review and course correction so that we all can get on track to end AIDS and keep all the promises enshrined in the SDGs,” said Dr Ishwar Gilada who is the longest serving HIV medical expert in India, is twice elected to the Governing Council of International AIDS Society (IAS) and Chairs IAS Asia Pacific.

“I think globally, regionally and here in India, we do have a choice. We can act now to end AIDS as a public health threat by 2030. We can actively work to keep people living with HIV on treatment and healthy. We can accelerate efforts to reduce new infections substantially and we can almost eradicate AIDS-related deaths. But to do so, we all will require firmer commitment by leaders to invest in effective programmes that engages community, further reduces stigma and discrimination, and addresses sustainability in the integration of the response. There is a pathway to ending AIDS, and we have a map. But are we bold enough to follow it and accelerate our progress?” said David Bridger, UNAIDS India Director at the 16th National Conference of AIDS Society of India (ASICON 2025).

THE DEADLY GAP: PROMISE VS REALITY

If every life counts, then we have to deliver on AIDS targets as well as all other SDGs. No excuse for inaction.

Some of the AIDS-related promises of our world leaders for 2025 are to ensure that:

· 95% of people at risk of HIV are using combination prevention options

· 95% of people with HIV know their HIV positive status

· 95% of those who know their HIV positive status are receiving lifesaving antiretroviral treatment

· 95% of those on treatment remain virally suppressed

· 95% of women access sexual and reproductive health services

· 95% of HIV positive pregnant women are receiving full services to prevent vertical transmission of HIV (during pregnancy, child birth and breastfeeding)

· 90% of people living with HIV are receiving TB preventive therapy

· 90% of people living with HIV and people at riskare linked to other integrated health services

· Less than 10% of people living with HIV and key populations experience stigma and discrimination

· Less than 10% of people living with HIV, women and girls and key populations experience gender-based inequalities and violence

· Less than 10% of countries have punitive laws and policies

WHY ARE WE FAILING TO DO WHAT WE KNOW WORKS!

The latest Global AIDS Update Report of the UNAIDS shows that most new HIV transmissions are attributed to among those who are undiagnosed, followed by those who are diagnosed but untreated, and then by those who are on antiretroviral therapy but not virally suppressed. There is “zero risk” of HIV transmission from those who are on treatment and virally suppressed or those whose viral load is undetectable (that is why it is referred to as undetectable equals untransmittable or U equals U).

To deliver on the 2025 targets, instead of 95% of people living with HIV knowing their status, only 78% were aware of it by 2023 in Asia Pacific. Instead of 90% of those knowing their status receiving the lifesaving antiretroviral therapy by 2023, only 67% were getting the medicines in the region. And instead of 86% of those on antiretroviral therapy remaining virally suppressed, only 65% were virally suppressed in the region by 2023.

“The alarming point is that in the Asia Pacific region, nearly a third of people living with HIV are not getting the care and support they need to stay healthy and prevent transmission” said UNAIDS India leader David Bridger “Asia Pacific has the second largest epidemic globally.”

Six countries in the Asia Pacific region have growing HIV epidemics: Bangladesh, Lau, Papua New Guinea, Afghanistan, Fiji, and the Philippines. In the Philippines HIV rates have increased by almost 600% during 2010-2023 (largely driven by male to male sex, predominantly among younger people). In the Fiji, HIV rates grew by over 200% during 2010-2023, largely driven by injecting drug use.

Nine countries of the region have increasing number of deaths due to AIDS-related illnesses: Pakistan, Indonesia, and Mongolia along with the above six countries where HIV rates are on a rise too.

However, some countries are doing better too to meet

GLOBALLY, 86% PEOPLE LIVING WITH HIV KNEW THEIR STATUS, 89% WERE ON ANTIRETROVIRAL THERAPY, AND 93% OF THOSE ON ANTIRETROVIRAL THERAPY WERE VIRALLY SUPPRESSED IN 2023.

2025 targets. These countries include: Cambodia, Nepal, New Zealand, and Thailand where over 80% of people living with HIV know their status, receive antiretroviral treatment and are virally suppressed.

Only 1 country in Asia Pacific has been able to keep the HIV prevention promise: Nepal. Four countries in Asia Pacific region have eliminated vertical transmission of HIV: Malaysia, Maldives, Sri Lanka and Thailand.

WHY ARE WE NOT-DOING-ALL-WHAT-WE-CAN

ON

HIV PREVENTION?

“Prevention efforts are not as powerfully being upheld. Only Nepal is on course to reach the target of 90% decline in new HIV infections by 2030,” said David. “In India, annual new HIV infections have declined by 44% during 2010-2023. We need far more acceleration of HIV prevention efforts here in India.”

“In 2024-2025, 84% of estimated people living with HIV in India were aware of their status, 86% of them were on lifesaving antiretroviral therapy, and 94% of them were virally suppressed,” said Dr Uday Bhanu Das of Indian government’s national AIDS programme (formally called as National AIDS Control Organisation (NACO), Ministry of Health and Family Welfare, Government of India).

Globally, 86% people living with HIV knew their status, 89% were on antiretroviral therapy, and 93% of those on antiretroviral therapy were virally suppressed in 2023.

WHY ENDING AIDS IN ASIA PACIFIC AND INDIA IS CRITICAL

“For the world to end AIDS, we must get it right here in Asia and the Pacific, but also in India because India has the second largest number of people living with HIV outside of South Africa,” said David.

Asia Pacific accounts for a quarter of the new HIV infections in the world: 300,000 new HIV infections in the region out of the total 1.3 million new infections worldwide in 2023. India accounted for 5-6% of the total new HIV infections globally in 2023.

If data alone does not drive the point home, then read this:

· Every 2 minutes in Asia Pacific region, one person is newly infected with HIV.

· Every hour this represents 35 people newly infected, including 9 young people.

· Every day, 300 men who have sex with men, 80 people who inject drugs, 50 sex workers and 15 transgender people become newly infected.

· Every hour 17 people die of an AIDS-related illness.

· And every day we lose 9 young people between the ages of 15 to 24 to AIDS-related illnesses in the region.

KEY POPULATIONS ARE KEY TO HIV RESPONSE

“HIV is concentrated among key populations and their partners. In 2022 in the Asia Pacific region, 4 out of every 5 new infections were among key populations and their sexual partners. This translates to nearly 80% of new infections were among key populations and their sexual partners. Of this, 43% were through male to male sex, which is an increase of over 34% over the past 10 years,” said David.

“Access to combination HIV prevention services among key populations throughout the region remains limited. HIV service coverage is near 47% for female sex workers, 31% for men who have sex with men, 34% for transgendered people and only 21% for people who inject drugs,” he added. “However, 9 countries in the region spend less than 15% of HIV budget on key population focussed programming.”

Pre-Exposure Prophylaxis (PrEP – a medicine taken to reduce the risk of HIV acquisition) has been available since 2012 (when US FDA had first approved it), but uptake is low in the region (2.5% of 2025 target): In 2023, only 204,000 people had used PrEP in Asia Pacific whereas the target was to reach over 8.2 million people by 2025.

HIV IS CONCENTRATED AMONG KEY POPULATIONS AND THEIR PARTNERS. IN 2022 IN THE ASIA PACIFIC REGION, 4 OUT OF EVERY 5 NEW INFECTIONS WERE AMONG KEY POPULATIONS AND THEIR SEXUAL PARTNERS.

DAVID BRIDGER, UNAIDS

INDIA DIRECTOR

TAKE THE RIGHTS PATH

David calls on governments for “renewing and intensifying focus on key populations” in terms of HIV response, health and social security. “We need to refocus and ensure that we are targeting the right populations with the right interventions in the right places - and - we are doing this at scale that will have the impact.”

“We need to modernise service delivery. This means adopting innovations, and using HIV combination prevention tools to their fullest - this includes PrEP, long-term injectables and HIV self testing. We also need to eliminate barriers to equitable HIV programme coverage which includes addressing legal and structural barriers that are fuelling stigma and discrimination,” he said. “We must invest more in HIV prevention and community-led programming.” HCMEA

USA – ElevateBio has entered a multi-year partnership with Amazon Web Services (AWS) to advance the development of gene-editing therapies using generative AI (genAI).

The collaboration aims to combine ElevateBio’s extensive CRISPR dataset and gene editing technologies with AWS’s powerful cloud computing and machine learning tools to speed up the discovery of novel therapeutics.

Through its gene editing and R&D division, Life Edit, ElevateBio offers a comprehensive platform that includes gene editing tools, RNA and cell engineering, and therapeutic delivery technologies.

With the integration of AWS’s SageMaker platform, ElevateBio will enhance its protein language models

SGS brings advanced FACS Technology to German Biopharma ElevateBio partners with AWS to advance CRISPR Therapeutics using Generative AI

SWITZERLAND — SGS, a global leader in testing, inspection, and certification, has launched Germany’s first commercial cell-sorting service designed for biopharmaceutical industries.

This innovative service employs the advanced BD FACSAria™ Fusion system, a state-of-the-art fluorescent-activated cell sorting (FACS) technology to accelerate the development of advanced therapeutic medicinal products (ATMPs) and promote innovation in cell and gene therapy.

Previously limited to academic settings, FACS technology is now commercially available through SGS. It enables precise cell characterization and sorting using both intra- and extracellular markers.

(PLMs), enabling faster and more accurate analysis of large datasets to design next-generation CRISPR systems.

A proof-of-concept study already showed that AWS’s tools improved protein discovery capabilities while reducing development costs.

The goal is to push CRISPR applications beyond rare monogenic diseases to include more complex genetic disorders, such as polygenic conditions.

This collaboration builds on ElevateBio’s strong growth trajectory, supported by a US$401 million Series D funding round in 2023.

The company joins a growing list of pharma players working with AWS, including Merck & Co. and Novartis,

This advancement allows biopharmaceutical companies to develop custom biomarkers, isolate rare cell populations, and leverage validated biomarker panels for applications in immunology and oncology.

The BD FACSAria™ Fusion system integrates seamlessly into laboratory workflows, enhancing efficiency and flexibility during analysis.

Equipped with four lasers and 16 fluorescence detectors, the system facilitates the parallel measurement of thousands of cells and biomarkers, including rare populations.

Its high-precision capabilities support single-cell sorting across up to 384 wells per plate, enabling the isolation, cultivation, and cryopreservation of rare cell populations.

Additionally, SGS operates this service in a biological safety level 2 (BSL-2) genetic engineering facility, which allows for examining genetically modified cells. This setup supports the early identification of toxic effects and the evaluation of therapeutic success.

To ensure sample stability, SGS has established a globally coordinated

which have tapped AWS for cloud services, analytics, and AI-driven solutions.

CRISPR technology gained significant traction after the FDA approved Casgevy—the first CRISPRbased therapy for sickle cell disease—in December 2023.

ElevateBio hopes to extend the therapeutic potential of CRISPR even further through AI-powered innovation.

Across the pharmaceutical industry, generative AI is becoming a key tool in preclinical development, promising lower costs, faster R&D timelines, and more targeted drug candidates.

The ElevateBio-AWS collaboration marks another step toward integrating AI with biotechnology to deliver transformative healthcare solutions.

network of laboratories that minimizes transfer times between sites. Downstream applications, such as immunological and molecular biological procedures, further enhance the service. By integrating this cuttingedge technology into its biologics testing portfolio, SGS reinforces its commitment to advancing patient therapies and supporting the success of biotherapeutics in Germany’s growing biopharmaceutical market.

FACS TECHNOLOGY ENABLES PRECISE CELL CHARACTERIZATION AND SORTING USING BOTH INTRA- AND EXTRACELLULAR MARKERS.

Tanzania expands TB detection with nationwide rollout of diagnostic machines

TANZANIA — In a major stride towards eliminating tuberculosis (TB), the Tanzanian government has distributed 185 modern diagnostic machines across all 26 mainland regions and two in Zanzibar.

The initiative, spearheaded by Health Minister Jenista Mhagama, aims to strengthen early detection, reduce TB transmission, and improve access to timely treatment— especially in underserved communities.

Speaking at the launch, Minister Mhagama underscored the government’s commitment to decentralizing healthcare services and bringing diagnostic capabilities closer to the people.

The deployment of these machines is complemented by a special programme targeting 76 councils across nine high-risk regions, where TB prevalence is especially concerning.

The goal is to actively identify and support individuals with TB, ensuring they are diagnosed and treated promptly.

TB continues to be a significant public health challenge in Tanzania, partly due to undetected cases caused by limited access to testing facilities.

The new machines are expected to close this gap, offering reliable diagnostic services even in remote and rural areas.

This expansion is in line with Tanzania’s national health priorities, which emphasize equitable access to quality healthcare and the eradication of communicable diseases.

The new infrastructure also reduces the need for patients to travel long distances for testing—an obstacle that has often resulted in delayed diagnoses and ongoing transmission in communities.

Minister Mhagama affirmed that the initiative places Tanzania at the forefront of regional efforts to combat TB, contributing meaningfully to the global goal of ending TB by 2030.

By merging advanced diagnostic technology with a strategically expanded healthcare network, Tanzania is setting a benchmark for other nations seeking to tackle TB and similar public health challenges through innovation, equity, and community-based care.

Siemens Healthineers Licenses CZT Technology from Kromek for Advanced SPECT Imaging

USA — Siemens Healthineers has partnered with Kromek Group Plc, a UK leader in radiation detection technology, to license its advanced cadmium zinc telluride (CZT) production technology.

This collaboration will enable Siemens Healthineers to manufacture CZT material in-house, a crucial component for gamma-ray detectors in single-photon emission computed tomography (SPECT) systems.

SPECT systems play a vital role in medical imaging, helping to diagnose conditions such as cancer, heart disease, and neurological disorders.

As part of the agreement, Kromek will transfer 15 of its CZT crystal-growing furnaces to Siemens Healthineers, along with essential intellectual property and technical expertise.

This partnership will enhance Siemens’ research, development, and manufacturing capabilities, paving the way for creating next-generation gamma-ray detectors for multimodal SPECT systems.

These advanced systems combine SPECT imaging with other modalities, providing physicians with more detailed and accurate diagnostic results.

Jim Williams, Head of Molecular Imaging at Siemens Healthineers, highlighted the importance of this partnership, stating that in-house production of CZT will allow the company to tailor the material to their specific applications while upholding high-quality standards.

This vertical integration aligns with Siemens’ strategy to improve performance and cost-efficiency across its molecular imaging technologies.

While Siemens Healthineers is advancing its CZT-based systems, the company is also continuing to develop sodium iodide (NaI)-based SPECT technologies.

NaI is a versatile material used in nuclear medicine applications, including theranostics, which combines therapy and diagnostics for personalized treatment.

However, CZT has distinct advantages over NaI, such as its ability to detect gamma radiation at room temperature without converting it to optical light.

This capability provides superior energy resolution, leading to more sensitive and precise imaging systems.

This multi-year agreement is expected to generate US$37.5 million for Kromek and significantly contribute to its profitability.

It also represents a key milestone in Siemens Healthineers’ efforts to enhance molecular imaging technologies for better healthcare outcomes.

Eli Lilly invests US$10M in Organovo’s FXR Agonist for IBD development

USA – Eli Lilly has entered into an agreement with San Diegobased Organovo Holdings to acquire full worldwide rights to its farnesoid X receptor (FXR) agonist programme, aimed at treating inflammatory bowel disease (IBD).

The deal includes a US$10 million upfront payment and up to US$50 million in milestone payments, according to a Securities and Exchange Commission (SEC) filing.

Central to the agreement is Organovo’s lead asset, FXR314, which has already been evaluated in a Phase II trial for metabolic dysfunction-associated steatohepatitis (MASH) and ulcerative colitis (UC). The company’s shares surged by 243% following the announcement on February 25.

FXR314 targets FXR, a nuclear hormone receptor involved in regulating carbohydrate and lipid metabolism, insulin sensitivity, and liver regeneration.

In November 2024, Organovo released Phase II data (NCT04773964) showing that FXR314 led to a statistically significant reduction in liver fat content in MASH patients.

At its highest dose, FXR314 achieved a 22.8% mean reduction compared to 6.1% in the placebo group. A larger proportion of patients also achieved more than a 30% fat reduction, with the drug maintaining a favourable safety profile.

Despite the promising MASH data, Organovo’s latest announcement with Lilly focuses exclusively on IBD.

A Phase II trial for IBD is slated to begin in Q4 2025. Previously, Organovo indicated FXR314 might also have applications in metabolic liver diseases and oncology.

The partnership comes amid broader skepticism about FXR agonists in MASH, following setbacks like Intercept Therapeutics’ failed bid to gain FDA approval for its FXR agonist, Ocaliva, in both MASH and primary biliary cholangitis (PBC). These failures led to workforce cuts and cast doubt on FXR-targeted therapies.

Meanwhile, alternative mechanisms have gained traction. Madrigal Pharmaceuticals’ Rezdiffra (resmetirom), a THRB agonist, became the first FDA-approved MASH therapy in March 2024.

Roche unveils Sequencing by Expansion (SBX) technology

GERMANY — Swiss pharmaceutical giant Roche has introduced its proprietary Sequencing by Expansion (SBX) technology, a significant leap forward for genetic research and healthcare.

This innovative platform integrates cutting-edge SBX chemistry with an advanced Complementary Metal Oxide Semiconductor (CMOS) sensor module, resulting in an ultrarapid, highly accurate, and exceptionally scalable sequencing system.

At the heart of SBX technology is a novel approach to encoding genetic information. Unlike traditional methods, SBX converts a target nucleic acid sequence—whether DNA or RNA—into a measurable surrogate polymer known as an Xpandomer.

These Xpandomers are approximately fifty times longer than the original molecule, allowing the technology to encode sequence information with a high signal-to-noise ratio.

This results in clear and robust signals with minimal background interference, which is crucial for achieving highly accurate single-molecule nanopore sequencing

The innovative CMOS-based sensor module’s integration supports parallel processing, enabling the sequencing platform to deliver real-time base calls and comprehensive analyses.

This feature is significant because it allows for the simultaneous processing of numerous samples, facilitating both high-throughput and flexible sequencing operations.

The technology’s versatility makes it suitable for a wide range of genomic applications, including whole genome and whole exome sequencing, as well as detailed RNA sequencing studies.

Next-generation sequencing has long been essential for deciphering genetic, genomic, and cellular information; however, the enhanced speed and efficiency offered by SBX technology promise to accelerate breakthroughs in understanding gene functions and interactions.

This is particularly important for understanding the complexities of diseases such as cancer, immune disorders, and neurodegenerative conditions, which involve interactions among hundreds or even thousands of genes.

Mark Kokoris and Robert McRuer, co-founders of Stratos Genomics, originally developed the SBX chemistry before Roche acquired it in 2020.

J&J’s Varipulse device teturns to US market with enhanced safety guidelines

USA – Johnson & Johnson has resumed the limited market release of its Varipulse heart device in the United States, following a temporary suspension that was initiated in January after four reported stroke incidents.

The precautionary pause came despite the device’s FDA approval and its use in over 130 U.S. cases at the time.

Varipulse utilizes pulsed field ablation (PFA), an advanced technique designed to treat atrial fibrillation by selectively ablating heart tissue responsible for abnormal rhythms, with minimal damage to surrounding structures.

While the initial rollout showed promise, the reported strokes prompted the company to halt all external evaluations and new case introductions to conduct a thorough investigation.

The subsequent review confirmed

that the device performs as intended, showing no variation in performance across global configurations.

However, the investigation highlighted a critical safety insight: the risk of neurovascular events could rise when multiple ablations are performed in quick succession (stacked) or conducted outside the pulmonary veins, especially in high volumes.

In response to these findings, Johnson & Johnson has issued a globally updated Instructions for Use (IFU) for the VARIPULSE™ Catheter. The revised IFU provides enhanced safety guidance to minimize procedural risks.

The company is proactively communicating these updates to clinicians, urging them to review the guidelines and integrate them into their practice to ensure patient safety.

Despite the temporary pause in the

U.S., the Varipulse device has now been used in over 3,000 commercial cases worldwide. Its return to the U.S. market underscores Johnson & Johnson’s dual commitment to medical innovation and rigorous safety standards.

The company continues to support healthcare providers with ongoing education and the latest clinical insights, reinforcing Varipulse’s role as a key tool in the treatment of atrial fibrillation.

PureHealth’s Pura App launches specialized diabetes care module

UAE - PureHealth, the largest healthcare group in the Middle East, has reported over 140,000 downloads of its AIpowered health app, Pura, since its launch in October 2023.

The app is designed to improve quality of life and longevity by providing users with personalized health insights and easy-to-use wellness tools.

Responding to user demand, Pura recently introduced a dedicated diabetes care module that simplifies condition management through real-time glucose tracking and customized meal planning.

It integrates with select continuous glucose monitoring devices and links directly to PureHealth’s Diabetes Command Centre, enabling healthcare professionals to monitor patient data securely.

This makes Pura the only app in the UAE connected to a physical healthcare network, offering a comprehensive solution for diabetes patients.

The app also supports various wearables, collecting real-time health metrics like blood glucose, heart rate, and sleep quality.

Pura features PureScore, the region’s first evidence-based health score, guiding users toward healthier lifestyle choices.

Gamification boosts engagement, including challenges that reward users with FitCoins, which can be redeemed for wellness benefits.

So far, over 5.7 million FitCoins

have been redeemed, and around 65% of users actively participate in app and community challenges, including those organized by the Active Abu Dhabi initiative.

Further enhancing user convenience, Pura integrates with PureHealth’s network of hospitals and clinics.

Users can book appointments, arrange home deliveries, access lab tests, and pay via insurance or self-pay, including a subscription model tailored for diabetes patients.

Looking ahead, PureHealth plans to introduce new features such as home sample collection to enhance healthcare access further.

Group CEO Shaista Asif emphasized that Pura empowers individuals to take control of their health journeys, supporting PureHealth’s mission to extend high-quality living in the UAE by 25 years over the next five decades.

FDA clears Zimmer Biomet’s metal-free knee implant for sensitive patients

USA - Zimmer Biomet Holdings, Inc. has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Persona® Revision SoluTion™ Femur, a next-generation knee implant designed specifically for patients with metal sensitivities.

Part of the broader Persona Revision Knee System, the new femoral component addresses a significant gap in orthopedic care for individuals allergic to metals like nickel, cobalt, and chromium.

Metal hypersensitivity affects 10–15% of the general population and up to 25% of patients with metallic implants, potentially causing pain, inflammation, and implant failure due to allergic reactions. Until now, treatment options for these patients were limited.

The Persona Revision SoluTion™ Femur is crafted entirely from Tivanium® (Ti-6Al-4V), a proprietary titanium alloy that has demonstrated reliable clinical performance for over 17 years.

This component is further enhanced through Zimmer Biomet’s unique Ti-Nidium Surface Hardening Process, which significantly boosts wear resistance and prevents the release of metal particles without incorporating common allergens.

Available in both standard and plus sizes, the implant allows surgeons to correct flexion instability and balance soft tissue, while avoiding implant overhang—a key consideration in joint revision procedures.

Joe Urban, President of Knees at Zimmer Biomet, said the FDA’s green light marks a major milestone for the company.

“This is the first metal alternative for individuals with sensitivities to common implant metals. We’re proud to provide a full revision knee construct that avoids nickel, cobalt, and chromium, aligning with our mission to address critical challenges in musculoskeletal health,” said Urban.

The Persona Revision SoluTion™ Femur is expected to be commercially available in the U.S. by Q3 2025, expanding Zimmer Biomet’s innovative portfolio in orthopedic care and offering much-needed relief for metal-sensitive patients.

Siemens Healthineers revolutionizes healthcare with Syngo Flexinity and Syngo Carbon Flexinity

GERMANY — Siemens Healthineers has introduced a groundbreaking approach to its imaging software solutions, designed to enhance efficiency and streamline access for healthcare providers.

This innovative strategy acknowledges the dynamic nature of clinical practice and addresses it through two distinct offerings: Syngo Flexinity and Syngo Carbon Flexinity.

Syngo Flexinity is specifically designed for CT and MRI applications, providing a comprehensive solution encompassing every imaging stage.

This platform is engineered for adaptability, from initial image acquisition and reconstruction to detailed image review and operational optimization.

It is particularly beneficial in environments characterized by fluctuating patient volumes and evolving operational requirements, offering a robust and flexible framework that supports standardized procedures and streamlined workflows.

Moreover, the platform’s operational optimization capabilities across large scanner fleets facilitate efficient staff planning and patient scheduling, addressing historical challenges related to consistency.

In contrast, Syngo Carbon Flexinity takes a broader approach by delivering advanced post-processing software that spans all imaging modalities.

This solution not only enhances visualization but also integrates artificial intelligence applications to support clinical decision-making.

By providing on-demand access to the latest advanced visualization technology and AI capabilities, healthcare professionals can make more informed and timely diagnoses.

A key advantage of Syngo Carbon Flexinity is its flexibility, allowing institutions to adjust their software usage as clinical requirements evolve without needing to anticipate future needs or commit to a fixed number of licenses.

This scalability eliminates the need for cumbersome purchasing processes for each upgrade or additional feature.

Siemens Healthineers has also implemented a pay-peruse pricing model that reinforces this flexibility, where customers pay only for the software they actually utilize, with costs calculated based on the annual volume of clinical cases processed.

Please

Telephone: Website:

Email:

What

What

Chairman,

Sales/Marketing

Director General Management

Purchasing/Supply chain

QA/R&D Process Management

Others (specify)

Applicant’s

Date: